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General introduction and aims of the thesis. 
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The prostate gland 
The prostate gland is an organ of the male reproductive system. It is located just below the bladder, 
around the urethra. In adolescents, the prostate is the size of a walnut and grows larger with age. 
The prostate fluid consists of enzymes that together with fluid from the seminal vesicles on the 
upper side of the prostate, forms an alkaline liquid to aid motility of spermatozoa. 
Histologically, the prostate consists of glands covered by two layers of epithelium, lying 
within fibromuscular stroma. The secretory luminal cells are inner, cuboidal to columnar cells 
with small round nuclei an no or inconspicuous nucleoli. Among the secretory products is the 
prostate specific antigen (PSA). The basal cells are the outer, flattened cells surrounded by a 
basement membrane. The prostatic and ejaculatory ducts flow into the urethra, running through 
the centre of the prostate. Neurovascular bundles run from apex to base at the lateral edges of the 
prostate.1 
 
Brief history of prostate cancer 
Cancer represents a paradox in our modern age. 
Although there is remarkable faith in our 
biomedical capability, we fail to comprehend the 
nature of cancer. The rise of morbid anatomy in 
the 16th century and postmortem pathology in the 
18th century was the first leap forward in 
understanding the aspects of death and disease. 
Andreas Vesalius was a physician from 
the Habsburg Netherlands, who was determined 
to investigate the human body based on careful 
observation, since medical knowledge at that 
time was not sufficiently based on human 
dissection. He wanted to open and read the body 
for himself. His tremendous objective was 
finalized in 1543 with the publication of De 
Humani Corporis Fabricia. The books became well-
known. Herein the prostate gland is illustrated 
for the first time. Vesalius had a crucial influence 
on the interest in postmortem anatomy. During 
the following centuries many tried to correlate 
clinical manifestations and postmortem 
 
Figure 1.1. Male genitalia, anterior view. 
Vesalius, A. De Humani Corporis Fabricia,  




observations. However, descriptions of the prostate were not sufficient enough to determine the 
nature of disease in men with urinary symptoms. 
Change came in the 19th century. When in 1853 dr. Adams wrote a letter about how his 
colleagues and he had come across a “very rare, scirrous disease” of the prostate, it must have 
been implausible to him that over 150 years later, it would be among the most common male 
malignancies.2 Earlier possible cases of prostate cancer were described, however unfortunately, 
the true origin of anomalies could not be determined by gross inspection alone.3 Examination of 
the body in dr. Adam’s case showed a scirrous tumour, meaning of firm and fibrous  
consistency, in the left lobe of the prostate. Dr. Adams was able to consult a microscopist, who 
had declared it to be ‘true scirrous in every particular’. When he showed his colleagues the growth 
was also present in iliac glands, all uncertainty regarding its nature was brought to an end. 
 
Clinical approach 
In the Netherlands, the incidence of prostate cancer is rising. Prostate cancer affected 12.646 men 
in 2018.4 The lifetime chance of prostate cancer diagnosis is 11%.5 Usually prostate cancer is 
asymptomatic, rarely patients present with urinary symptoms or hematuria. The cause of these 
symptoms, however, often lies with benign prostatic hyperplasia (BPH). BPH is a common disease 
among elderly men, affecting 50% of men at age 50 and 80% of men at age 80.6 Elevated PSA 
levels and abnormal findings on digital rectal examination raise clinical suspicion for prostate 
cancer. Currently, prostate cancer is diagnosed using biopsies taken with multiresonance imaging 
(MRI) and/or ultrasound. When the pathologist confirms the diagnosis of cancer on biopsies, 
patients become eligible for either surveillance or active treatment.  
Although prostate cancer has a high prevalence and it is the secondary cause of death 
among males, most men will not die from their disease. Low risk prostate cancer is a slow growing 
malignancy, unlikely to decrease life expectancy. Therefore, active surveillance has become a 
widely acceptable alternative for surgery in patients with low risk prostate cancer. With the use of 
risk calculation models, patients who will not benefit from therapy are identified and monitored 
instead.7 A bi-annual urologists’ appointment with measurement of PSA levels and a digital rectal 
examination are used to monitor and detect disease progression. Also, repeat prostate biopsies are 
taken when PSA levels rise. 
Surgery is a common treatment for intermediate to high risk prostate cancer. 
Laparoscopic robot-assisted radical prostatectomy is a curative strategy, however considerable 
potential side effects are urinary incontinence and erectile dysfunction. Other treatment strategies 
include radiation or hormone therapy. Radiation therapy can be used as initial treatment for low 
grade tumours as well as high grade tumours, and for tumours growing outside the prostate. When 
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prostate cancer surgery did not succeed in complete removal of the malignancy, or in case of 
disease progression, men are treated with radiation therapy. Radiation affects the surrounding 
tissues as well and may cause symptoms of bladder and bowel injury, sexual dysfunction, skin 
irritation and fatigue. Hormone therapy interferes with the need of prostate cancer cells for male 
hormones. Androgens are growth stimuli for prostate cancer cells. Deprivation of these hormones 
causes reduced growth and even shrinkage of the malignancy. Both radiation and hormone 
therapy are often used without curative intent, when the prostate cancer is too widespread, to 










Figure 1.2. A. Modified Gleason grading system based on the ISUP 2014 consensus meeting. B-E. Gleason 
grade 4 growth patterns with ill-formed (B), fused (C), glomeruloid (D) and cribriform glands (E). F-G. 
Intraductal carcinoma can mimic invasive cribriform carcinoma on HE staining (F), however, basal cell 





For decades, the Gleason grading system has been the fundamental way for pathologists to classify 
prostate cancer. In 1966, dr. Donald Gleason developed the histological classification based solely 
on architectural growth patterns of prostate cancer, rather than by cytological nuclear atypia, to 
bring order into the morphological heterogeneity.8 Within the same tumour, different architectural 
growth patterns can be identified. Dr. Gleason distinguished five elementary patterns and 
suggested each tumour would be assigned two patterns: the primary, most common architectural 
pattern, followed by the secondary pattern. After validation, the Gleason grading system was 
incorporated in pathology departments worldwide and is one of the most important predictive 
parameters in prostate cancer outcome.9, 10 The International Society for Urological Pathology 
(ISUP) modified the grading system during consensus meetings in 2005 and 2014, leading to the 
Gleason score as known today.11, 12 
 
• Gleason grade pattern 1 and 2 were initially described as well differentiated glands, with 
little variation in size, forming a circumscribed tumour mass. Some cases later appeared 
to be mimickers of cancer. This, together with histomorphological similarity to pattern 3 
and the inability to distinguish these patterns on biopsies, made the patterns obsolete. 
Therefore, nowadays the lowest possible score of prostate cancer according to the 
Gleason grading system is 3 + 3 = 6. 
• Gleason grade pattern 3 consist of well delineated invading glands, with marked 
variation in size and shape and lined with one layer of epithelial cells. The epithelial cells 
show slightly pale or basophilic cytoplasm and mild to moderate atypia with enlarged 
nuclei and visible nucleoli. 
• Gleason grade pattern 4 comprises four major growth patterns. Ill-defined glands are 
irregular with poorly formed lumina. Fused glands form interconnecting structures with 
increased complexity. Cribriform growth shows a field of glands with punched out 
lumina without intervening stroma. Glomeruloid glands resemble the glomerulus of the 
kidney. They are dilated glands wherein a proliferation of tumour cells is present, 
attached to one side of the gland wall. The proliferation might have a cribriform aspect. 
• Gleason grade pattern 5 is devoid of glandular differentiation and is composed of single 
cells, cords or sheets of cells. Pattern 5 may also show solid or cribriform fields with 
comedonecrosis. 
In 2016, the World Health Organization (WHO) and ISUP proposed a grouping system, based on 
the modified Gleason grading system, in order to distinguish clinically significant patient groups.12 
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The Grade Groups comprise Grade Group 1 (Gleason score ≤6), Grade Group 2 (Gleason score 
3 + 4 = 7), Grade Group 3 (Gleason score 4 + 3 = 7), Grade Group 4 (Gleason score 8) and Grade 
Group 5 (Gleason score 9 and 10). 
 
Cribriform prostate cancer 
Last decade, cribriform growth in prostate cancer has been recognized as highly 
significant subtype of Gleason grade pattern 4. In 2011, Iczkowski et al. were the first to relate 
cribriform growth to adverse outcome.13 They reported worse biochemical recurrence-free survival 
in patients with cribriform prostate cancer compared to patients without the pattern. To date, 
cribriform growth has been linked to advanced stage, worse biochemical recurrence-free survival, 
metastasis and disease-specific death in biopsies as well as in radical prostatectomy specimens.14-
17 Cribriform carcinoma is associated with increased genomic instability and harbours distinct 
genomic alterations.18 Remarkably, cribriform growth pattern used to belong in the Gleason grade 
3 group, but was reassigned to grade 4 in 2005. Hitherto, the clinical significance of cribriform 
growth has been acknowledged. However, there is a need to elucidate heterogeneity among 
cribriform growth patterns and their individual prognostic value. 
Although cribriform growth is a high risk pattern compared to ill-defined and fused 
growth patterns, little is known about the clinical significance of glomeruloid growth. Few studies 
reported on the glomeruloid pattern and they show contradictory results.16, 19 Lotan et al. reported 
an association between glomerulations and concurrent high grade carcinoma and cribriform 
growth on prostate biopsies.19 Others could not find an association with glomeruloid growth and 
worse outcome.20, 21 The study of Kweldam et al. even showed a trend towards favourable outcome 
in Gleason score 7 prostate cancer on radical prostatectomy.16 
The clinical significance of intraductal carcinoma of the prostate (IDC-P) has been 
acknowledged as well, although this lesion is not incorporated in the 2014 Gleason grading system. 
Intraductal carcinoma is defined as an expansile proliferation of atypical secretory epithelial cells 
within pre-existent prostatic ducts.22, 23 Intraductal carcinoma often shows cribriform architecture, 
but may also have solid or papillary appearance. Invasive cribriform carcinoma and cribriform 
intraductal carcinoma of the prostate can be distinguished by the presence of basal cells 
surrounding intraductal carcinoma, since they belong in the normal gland epithelium. Presence of 
intraductal carcinoma has been associated with advanced tumour stage, concurrent high grade 
invasive carcinoma and worse outcome, including biochemical recurrence and metastasis.24-28 The 
origin of intraductal carcinoma is yet unclear, as proposed concepts include retrograde glandular 
colonization from a common denominator with invasive cribriform growth as well as a 




Aims of the thesis 
The general scope of this thesis is to study histomorphological growth patterns in prostate cancer 
and to identify favourable parameters for intermediate and high grade prostate cancer. In more 
detail, the aims of this thesis are 
 
• To study variants of cribriform growth, especially small and large invasive cribriform 
prostate cancer and intraductal cribriform prostate cancer in radical prostatectomy 
specimens. (Chapter 2) 
 
• To investigate concordance of cribriform growth on biopsies and radical prostatectomy 
specimens and to identify predictive parameters for presence of cribriform growth. 
(Chapter 3) 
 
• To study the prognostic value of cribriform-negative prostate cancer in intermediate risk 
cancer in radical prostatectomy specimens. (Chapter 4) 
 
• To elucidate the morphology and effect on clinicopathological outcome of glomeruloid 
Gleason pattern 4. (Chapter 5) 
 
• To stratify high risk prostate cancer according to presence of cribriform growth in radical 













Large cribriform growth pattern identifies Grade Group 2 




Hollemans E, Verhoef EI, Bangma CH, Rietbergen J, Helleman 
J, Roobol MJ, van Leenders GJHL.  





Invasive cribriform and intraductal carcinoma are associated with adverse clinical outcome in 
patients with Gleason score 7 prostate cancer. It is yet unclear whether invasive cribriform and 
intraductal carcinoma of the prostate both have independent prognostic value, or whether field 
size of invasive cribriform carcinoma has impact on disease outcome. Our objective was to 
determine the prognostic impact of intraductal and invasive cribriform prostate cancer histological 
subtypes in radical prostatectomies. 
We reviewed 420 prostatectomy specimens with Grade Group 2 prostate cancer, 
assessed the percentages of Gleason grade 4 and tertiary 5, and performed immunohistochemistry 
for basal cells to discriminate intraductal from invasive cribriform growth. Small and large invasive 
cribriform fields were distinguished based on a diameter of at least twice the size of adjacent pre-
existent normal glands. Clinicopathological parameters and biochemical recurrence-free survival 
were used as endpoints.  
Cribriform architecture was observed in 228 (54.3%) men, 103 (24.5%) of whom had 
intraductal, 194 (46.2%) small invasive and 34 (8.1%) large invasive cribriform growth. Large 
invasive cribriform architecture was associated with older age (P<0.001), higher percentage 
Gleason grade 4 (P=0.001), extraprostatic expansion (P<0.001) and more frequent lymph node 
metastases (P=0.002), when compared with small invasive cribriform and/or intraductal 
carcinoma. Univariate analysis identified PSA, pT-stage, surgical margin status, intraductal and 
invasive cribriform growth as significant predictors for biochemical recurrence-free survival. In 
multivariable Cox regression analysis, pT-stage (hazard ratio 1.64, 95%CI 1.02-2.63, P=0.04), 
positive surgical margins (hazard ratio 3.28, 95%CI 2.06-5.23, P<0.001) and large cribriform 
growth (hazard ratio 4.36, 95%CI 2.08-9.17, P<0.001) were independent predictors for 
biochemical recurrence-free survival, while intraductal carcinoma, small cribriform growth, and 
percentage of Gleason grade 4 were not.  
In conclusion, large cribriform fields represent an aggressive sub-pattern of invasive 
cribriform prostate cancer and are an independent predictive factor for biochemical recurrence-








The Gleason score is one of the most important parameters for clinical decision-making in men 
with prostate cancer. The Gleason grading system is entirely based on tumour architectural growth 
patterns which are classified into five different grades. While men with biopsy Gleason score 6 are 
frequently eligible for active surveillance, treatment is warranted in patients with Gleason score 8-
10. The optimal therapeutic strategy for individual patients with Gleason score 7 is not yet clear. 
While most patients with Gleason score 7 undergo radical prostatectomy or radiation therapy, 
active surveillance is increasingly being considered in this large group of men. Therefore, there is 
an urgent need for additional parameters to aid therapeutic decision-making in men with Gleason 
score 7 prostate cancer. 
Gleason score 7 prostate cancer is composed of well-delineated Gleason grade 3 glands 
along with Gleason grade 4 structures. Gleason grade 4 prostate cancer is heterogeneous, 
comprising a range of growth patterns, categorised as poorly formed, fused, glomeruloid and 
cribriform.12, 31 These individual growth patterns are generally not specified in pathology reports, 
however several studies have found that patients with invasive cribriform growth have a worse 
outcome than men without this pattern.13-17, 32, 33 Among cribriform prostate cancers heterogeneity 
of architectural pattern is still present, with some areas being round and small, while others are 
large and confluent vastly exceeding pre-existent gland diameter.11, 34 
Intraductal carcinoma of the prostate is characterised by either cribriform or solid 
malignant epithelial proliferation, or loose cribriform and micropapillary formations of severely 
atypical cells, in pre-existent large acini and prostatic ducts, with preservation of basal cells. 12 
Although intraductal carcinoma is formally not included in the Gleason score, numerous studies 
have linked intraductal carcinoma to more aggressive disease.25, 28, 34-37 The presence of intraductal 
carcinoma ought thus to be routinely noted in pathology reports.12, 38 
Invasive cribriform Gleason grade 4 prostate cancer and intraductal carcinoma often 
coexist, and can be difficult to distinguish without the use of immunohistochemical staining of 
basal cells. At present, it is not clear whether invasive cribriform carcinoma and intraductal 
carcinoma both have independent prognostic value for prostate cancer, or whether invasive 
cribriform sub-patterns have additional prognostic value. 16, 39 The objective of this study is to 
determine the outcome of invasive cribriform sub-patterns and intraductal carcinoma in patients 
with Grade Group 2 after radical prostatectomy. 
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Materials and methods 
 
Patient selection 
In total 854 patients were identified who had undergone radical prostatectomy for prostate 
adenocarcinoma at the Erasmus MC, Rotterdam, The Netherlands between 2000 and 2017. Men 
who had undergone hormonal, radiation or viral therapy (n=19) prior to operation were excluded 
from this study.40 After fixation in neutral-buffered formalin, the radical prostatectomy specimens 
were sectioned transversely and entirely embedded for diagnostic purposes. All slides and blocks 
were available for pathology review. The use of tissue samples for scientific purposes was approved 
by the institutional Medical Research Ethics Committee (MEC-2011-295, MEC-2011-296). 
Samples were used in accordance with the “Code for Proper Secondary Use of Human Tissue in 
The Netherlands” as developed by the Dutch Federation of Medical Scientific Societies (FMWV, 
version 2002, update 2011). 
 
Pathologic evaluation 
Two investigators blinded to clinical outcome (EH, GvL) reviewed all radical prostatectomy 
specimens (n=854). The following features were recorded: Gleason score according to the 
WHO/ISUP 2014 guidelines, pT-stage according to the AJCC TNM 8th edition, surgical margin 
status, presence of intraductal carcinoma, percentage Gleason grade 4, including specific growth 
patterns, and presence of tertiary Gleason grade 5.12, 41 Based on this revision, Grade Group 2 
specimens were identified. The following Gleason grade 4 growth patterns were recognised: poorly 
formed, fused, glomeruloid and cribriform glands.12, 38 In addition, we distinguished small and 
large cribriform growth patterns. Small cribriform structures had a diameter less than twice the 
size of adjacent benign glands. Large cribriform pattern was defined as having a diameter of at 
least twice the size of adjacent pre-existent normal glands, and could either represent one large 
well defined cribriform field or a confluent cribriform area (Figure 2.1). Invasive cribriform 
Gleason grade 4 was morphologically distinguished from intraductal carcinoma based on the 
following features: invasive cribriform prostate cancer had irregular outline, showed anastomosing 
fields beyond pre-existent gland architecture or extension into periprostatic adipose tissue, 
ejaculatory ducts or seminal vesicles. Intraductal carcinoma was morphologically identified if 
cribriform structures were clearly continuous with pre-existent glands lined by normal basal 
epithelium, or containing corpora amylacea. Where invasive cribriform carcinoma and intraductal 
carcinoma could not be differentiated by morphological criteria alone, additional 




from 156 Grade Group 2 patients were stained. Gleason grade 5 was considered as a tertiary 
pattern if it occupied less than 5% of the total tumour area.12, 31, 38 
 
Immunohistochemistry 
Four micrometer thick tissue sections were cut from selected paraffin-embedded blocks and 
mounted on slides (Superfrost Microscopic Slides, ThermoFisher Scientific, Bleiswijk). Slides 
were deparaffinised and rehydrated with xylene and ethanol. Endogenous peroxidase was blocked 
using 0.3% H2O2 in PBS. Heat-induced antigen retrieval was accomplished by 15 min in Tris-
EDTA buffer (pH 9; Klinipath, Duiven, The Netherlands). Mouse monoclonal high molecular 
weight cytokeratin (clone 34BE12; 1:200; DAKO; Heverlee, Belgium) diluted in normal antibody 
diluent (APG-500; ScyTek Laboratories, West Logan, USA) was incubated for 2h at room 
temperature. Antibody visualization was performed with Envision kit (DAKO) and slide 
counterstaining with hematoxylin. When basal cell staining was completely absent around a 
cribriform gland, it was categorised as invasive cribriform carcinoma; if sporadic, scattered or 
continuous basal cells were identified the structure was classified as intraductal carcinoma.  
 
Clinical follow-up 
Clinical follow-up after radical prostatectomy consisted of six-monthly, and later annual 
monitoring of serum PSA levels. Biochemical recurrence was defined as PSA level ≥ 0.2 ng/ml 
measured at two separate time points at least three months apart when PSA had been undetectable 
after operation, or as PSA increase of > 2.0 ng/ml if serum PSA had not declined to zero after 
operation. Post-operative lymph node and distant metastases were confirmed by biopsy or 
multidisciplinary consensus. Biochemical recurrence-free survival was defined as time in months 
from radical prostatectomy to biochemical recurrence. 
 
Statistical analysis 
Normally distributed, continuous variables were analysed using the independent sample Student’s 
t-test, whereas variables without normal distribution were analysed using the Mann-Whitney U 
test. Pearson’s chi squared (χ2) test was used for categorical parameters. Percentage Gleason grade 
4 was analysed both as continuous and dichotomous parameter (≥5% and <25% versus ≥25% and 
<50%). Missing PSA values (n=27) were imputated using the median PSA value. Biochemical 
recurrence-free survival was analysed using Cox proportional hazards regression and visualised by 
Kaplan-Meier curves, excluding patients with lymph node metastases at time of operation. 
Statistics were performed using SPSS version 24 (IBM, Chicago, IL, USA). Results were 
considered significant when the two-sided P-value was <0.05. 
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Figure 2.1. Gleason grade 4 cribriform growth patterns and intraductal carcinoma. A. Small invasive 
cribriform carcinoma, 10x. B. Large invasive cribriform carcinoma, 10x. C-D. Intraductal cribriform 









Out of the 854 revised patients, 420 showed Grade Group 2 at radical prostatectomy and were 
included in this study. Median age at radical prostatectomy was 64.6 years (interquartile range 
59.8-68.1) and median PSA level was 8.2 ng/ml (interquartile range 5.9-12.6). The tumour stage 
was distributed as follows: pT2 (n=234; 55.7%), pT3a (n=153; 36.4%) and pT3b (n=33; 7.9%). A 
positive surgical margin was present in 142 cases (33.8%). In total 241 men (57.4%) had undergone 
pelvic lymph node dissection at the time of radical prostatectomy; in 12 patients (2.9%) one or 
more lymph node metastases were present. 
Poorly formed glands (n=325; 77.4%) were the most common Gleason grade 4 pattern 
followed by fused (n=290; 69.0%), cribriform (n=204; 48.6%) and glomeruloid (n=194; 46.2%) 
glands. Seventy-five patients (17.9%) had one Gleason grade 4 pattern, 152 (36.2%) two, 133 
(31.6%) three and 60 (14.3%) four growth patterns. Tertiary grade 5 was present in 49 (11.6%) 
men. 
In total, 228 (54.3%) patients showed either invasive or intraductal cribriform carcinoma. 
These patients had higher PSA levels (mean 12.2 ng/ml versus 9.4 ng/ml; P=0.006) than those 
without cribriform architecture. They also more frequently had extraprostatic extension (51.8% 
versus 35.4%; P<0.0001) and positive surgical margins (39.5% versus 27.1%; P=0.007). One 
hundred and fifty (65.8%) patients with cribriform architecture and 91 (47.4%) patients without 
cribriform architecture had undergone pelvic lymph node dissection at the time of radical 
prostatectomy. Twelve (8.0%) of the patients with cribriform architecture were found to have 
lymph node metastasis at time of radical prostatectomy, compared to none in the group without 
cribriform architecture (P=0.006). 
 
Comparison of invasive cribriform and intraductal carcinoma 
Detailed histopathological and immunohistochemical analysis revealed that invasive cribriform 
carcinoma was present in 204 (48.6%), and intraductal carcinoma in 103 (24.5%) cases. Solid and 
loose papillary morphological variants of intraductal carcinoma were rarely observed, and co-
existed with cribriform intraductal carcinoma in each case. Seventy-nine (18.8%) men had both 
intraductal carcinoma and invasive cribriform carcinoma, while 24 (5.7%) patients had intraductal 
carcinoma without invasive cribriform growth. Invasive cribriform growth without intraductal 
carcinoma was present in 125 men (29.8%). PSA levels (P=0.06), pT stage (P=0.32), surgical 
margin status (P=0.36) and occurrence of lymph node metastasis (P=0.39) were not significantly 
different between patients with invasive cribriform carcinoma without intraductal carcinoma 
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(n=125) and men with intraductal carcinoma only (n=24). Patients with both invasive cribriform 
and intraductal carcinoma (n=79) more frequently had extraprostatic extension (60.8% versus 
46.4%; P=0.02) and lymph node metastasis (11.4% versus 1.6%; P=0.003) than those with invasive 
cribriform growth without intraductal carcinoma; there was no statistically significant difference 
in PSA level (P=0.07), pT stage (P=0.64), surgical margin status (P=0.20) and lymph node 
metastasis (P=0.32) between men with combined invasive cribriform and intraductal carcinoma, 
and intraductal carcinoma only. 
 
Large invasive cribriform carcinoma 
Large invasive cribriform growth was observed in 34 (8.1%) patients. All of these men (100%) had 
concomitant small invasive cribriform growth and 24 (70.6%) had intraductal carcinoma (Table 
1.1). We compared patients with invasive large cribriform growth with men who had either small 
invasive cribriform growth and/ or intraductal carcinoma (n=194). The age of patients with large 
cribriform architecture (66.2 years; interquartile range 63.3-70.9) was higher (P=0.03) than of men 
with small cribriform architecture (63.8 years; interquartile range 60.1-67.8). Albeit PSA levels of 
men with large cribriform architecture were higher (15.0 ng/ml; interquartile range 8.3-18.3) than 
in those with small cribriform architecture (11.8 ng/ml; interquartile range 6.0-13.4), this did not 
reach significance in this cohort (P=0.16). In total 23/34 (67.7%) patients with large cribriform 
pattern had extraprostatic extension (pT3) as compared to 96/194 (49.0%) with small cribriform 
pattern (P<0.001), although positive surgical margins were more frequently observed in the latter 
group (23.5% versus 42.3%; P=0.04). The total percentage of Gleason grade 4 was 30.0% 
(interquartile range 20%-40%) in large and 23.3% (interquartile range 15%-30%) in small 
cribriform pattern (P=0.001). Tertiary Gleason grade 5 was observed in 8/34 (23.5%) patients with 
large and 23/194 (11.9%) with small cribriform architecture, but this difference did not reach 
conventional measures of significance (P=0.07). Lymph node metastases were observed in 6/26 
(23.1%) men with large cribriform architecture and in 6/124 (4.8%) with small cribriform 
architecture (P=0.002).  
 
Clinical outcome of invasive and intraductal carcinoma 
The median follow-up of Grade Group 2 patients without positive lymph node dissection at time 
of radical prostatectomy (n=408) was 53 months (interquartile range 12.7-99.1). During follow-up 
86 men experienced biochemical recurrence after a median of 26 (interquartile range 10.7-47.6) 
months. Biochemical recurrence occurred more frequently (χ2, P=0.01) in the large invasive 
cribriform (13/28; 46.4%) than in the small invasive cribriform and/or intraductal group (44/188; 




P=0.04). The median time to biochemical recurrence was significantly shorter (log rank, P<0.001) 
in patients with large invasive cribriform growth (11 months; interquartile range 2.6-37.2) than in 
patients with small cribriform growth (25 months; interquartile range 11.3-39.3) and no cribriform 
architecture (43 months, interquartile range 15.4-73.8) (Figure 2.2). 
Univariate analysis showed that PSA (hazard ratio 1.02, 95% CI 1.01-1.04; P=0.0001), 
pT3a (hazard ratio 2.00, 95% CI 1.27-3.14; P=0.003), pT3b (hazard ratio 4.42, 95% CI 2.24-8.72; 
P<0.001), positive surgical margins (hazard ratio 3.24, 95% CI 2.11-4.97; P<0.0001), intraductal 
carcinoma (hazard ratio 2.13, 95% CI 1.36-3.36; P=0.001) and any invasive cribriform growth 
(hazard ratio 1.78, 1.16-2.74; P=0.008) were all significant predictors for biochemical recurrence-
free survival (Table 2.2). Percentage Gleason grade 4 was neither predictive as a continuous 
(hazard ratio 1.01, 95% CI 0.99-1.03, P=0.076) nor as a dichotomised parameter (hazard ratio 
1.26, 95% CI 0.82-1.93, P=0.29). Tertiary Gleason grade 5 (hazard ratio 1.29, 95% CI 0.66-2.50, 
P=0.46) did not have predictive value for biochemical recurrence in this cohort. In multivariable 
analysis, extraprostatic extension (pT3a, hazard ratio 1.64, 95% CI 1.02-2.63, P=0.04), seminal 
vesicle invasion (pT3b, hazard ratio 3.00, 95% CI 1.42-6.34, P=0.004), positive surgical margins 
(hazard ratio 3.28, 95% CI 2.06-5.23, P<0.0001) and invasive large cribriform architecture (hazard 
ratio 4.36, 95% CI 2.08-9.17, P=0.0001) were independent predictors for biochemical recurrence-
free survival, while small invasive cribriform growth pattern and intraductal carcinoma were not. 
To determine whether the difference in prognostic value between invasive small and large 
cribriform growth could be explained by an overall higher percentage of cribriform growth, we 
compared the outcome of patients with ≥5% invasive cribriform growth and those with <5%. 
When invasive cribriform growth was present, no statistical difference existed between low and 
high cribriform percentage (log rank; P=0.087). 
During follow-up 13 patients developed bone metastases. Nine of these patients had 
small invasive cribriform or intraductal carcinoma (4.6%) and four had invasive large cribriform 
carcinoma (11.8%) at radical prostatectomy. The median time to bone metastasis was 138 months 
(interquartile range 109.4-172.6) for small invasive and intraductal cribriform carcinoma and 59 
months (interquartile range 17.9-114.8) for invasive large cribriform carcinoma. Due to the low 
number of events we were not able to perform further statistical analysis. 
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Table 2.1. Clinicopathological characteristics of Grade Group 2 patients at radical prostatectomy. 
Non-cribriform cases do not have invasive cribriform carcinoma or intraductal carcinoma. Small 
cribriform cases include men with small invasive cribriform carcinoma and/or intraductal 
carcinoma. Large cribriform cases represent patients with presence of large invasive cribriform 
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Positive surgical Margin  
 
52 (27.1) 82 (42.3) 8 (23.5) 0.042 
Intraductal carcinoma 
 
0 79 (40.7) 24 (70.6) 0.0012 
IDC vs invasive cribriform 
  IDC -/invasive cribriform - 
  IDC +/invasive cribriform - 
  IDC -/invasive cribriform + 




















Tertiary Gleason  5 
 
18 (9.4) 23 (11.9) 8 (23.5) 0.072 
PLND 
 

























29 (15.1) 48 (24.7) 18 (52.9) 0.0012 
Distant metastasis 
 
0 9 (4.6) 4 (11.8) 0.102 
Values denote either mean (median; interquartile range) or n (%).P-values correspond to the comparison 
between small invasive cribriform and/or intraductal carcinoma and large invasive cribriform groups. 
1Student’s t-test. 





Figure 2.2. Biochemical recurrence-free survival of Grade Group 2 patients, stratified for absent, 




Table 2.2. Cox regression analysis of biochemical recurrence-free survival in Grade Group 2 
prostate cancer patients without lymph node metastasis at time of operation (n=408).  
 
 Univariate analysis Multivariable analysis 
 HR 95% CI P-value HR 95% CI P-value 
Age 0.99 0.96 - 1.03 0.56 0.99 0.95 - 1.03 0.57 
PSA 1.02 1.01 - 1.04 <0.001 1.01 0.99 - 1.02 0.34 
pT-stage 
  T2 
  T3a 







1.27 - 3.14 











1.02 - 2.63 







3.24 2.11 - 4.97 <0.001 3.28 2.06 - 5.23 <0.001 
Percentage 
Gleason 4 
1.26 0.82 - 1.93 0.29 0.94 0.59 - 1.51 0.80 
Tertiary Gleason 5 1.29 0.66 - 2.50 0.46 0.95 0.44 - 2.06 0.90 
Intraductal 
carcinoma 
2.13 1.36 - 3.36 0.001 1.32 0.77 - 2.25 0.31 
Invasive cribriform 
  Small 





0.95 - 2.37 








0.65 - 1.75 








While most patients with Grade Group 2 prostate cancer are treated with radiotherapy and/or 
surgery, active surveillance is increasingly being considered as alternative strategy for these men.42-
46 Further risk stratification in this large group of patients is necessary to support therapeutic 
decision-making. Recently, invasive cribriform carcinoma and intraductal carcinoma have been 
recognised as promising additional predictive parameters for men with Grade Group 2 prostate 
cancer.14, 16, 32, 34, 47 In the current study, invasive and/or intraductal cribriform carcinoma was 
present in 54.3% of radical prostatectomies with Grade Group 2 prostate cancer. While the 
clinicopathological features of men with invasive cribriform carcinoma without cribriform 
intraductal carcinoma were not statistically significant from those with cribriform intraductal 
carcinoma only, patients with both invasive and intraductal cribriform carcinoma more often had 
extraprostatic extension and lymph node metastasis than those with invasive cribriform carcinoma 
only. Furthermore, we found that patients with large invasive cribriform growth had higher pT-
stage and more frequent positive lymph nodes than those with small invasive and/or intraductal 
cribriform carcinoma. In multivariable analysis, large invasive cribriform carcinoma was an 
independent predictor for biochemical recurrence-free survival, while small invasive carcinoma 
and intraductal cribriform carcinoma were not.  
Various studies have addressed the association of either invasive cribriform carcinoma 
or intraductal carcinoma with adverse features at prostatectomy and with clinical outcome. 14-16, 20, 
34 We observed that invasive and intraductal cribriform carcinoma were present in respectively 
48.6% and 24.5% of prostatectomy specimens with Grade Group 2 prostate cancer. These rates 
are comparable to those found by others. Trudel et al. for instance found intraductal carcinoma in 
17.5%, invasive cribriform carcinoma in 45.6% and both invasive and intraductal cribriform 
carcinoma in 36.8% of 57 prostate specimens.34 In a cohort of 286 Grade Group 2 prostate cancer 
patients, Choy et al. demonstrated intraductal carcinoma in 26.5% and invasive cribriform growth 
in 38.7%.20 Two studies took into account large cribriform architecture, however these used 
different thresholds.13, 34 Iczkowski et al. defined large cribriform pattern as having more than 12 
luminal spaces, while area size exceeding the size of an average benign gland was used by Trudel 
et al. Our threshold of large cribriform fields as at least twice the size of normal adjacent glands, 
exceeds that of previous studies. For instance, in the study of Iczkowski et al. no cases were present 
with small cribriform pattern only, while small invasive cribriform carcinoma was present in 40% 
of our cases. To elucidate the clinical and biologic relevance of invasive cribriform and intraductal 




In a previous case-control study of 161 men with Gleason score 7 at radical 
prostatectomy, we found invasive cribriform but not intraductal carcinoma to be a significant 
predictive marker for metastasis- and disease specific-free survival in multivariate analysis.16 In a 
subsequent analysis of prostate biopsies with long term follow-up, both invasive and intraductal 
carcinoma had predictive value for disease-specific death, and combining both lesions had the 
strongest prognostic value.32 The prognostic value of invasive and intraductal carcinomas at 
biopsies does not always correspond with the prognostic value at radical prostatectomies. 
Sampling artifacts inherently associated with diagnostic biopsies are likely the cause of 
discrepancies between biopsies and radical prostatectomy specimens. This is for instance reflected 
by the frequency of cribriform growth in biopsies and resection specimens; while invasive and/or 
intraductal cribriform architecture was found in 17% of sextant biopsies with Grade Group 2, it 
was present in 54.3% of radical prostatectomy specimens in the current study.32 Since most biopsy 
schedules currently include between 8 and 16 biopsies, and biopsies are increasingly being targeted 
by Magnetic Resonance Imaging (MRI), the frequency of invasive cribriform and/or intraductal 
carcinoma is higher with fewer sampling artifacts.48, 49 Since both small cribriform growth and 
intraductal carcinoma are often associated with large cribriform growth, these patterns should still 
be reported. 
The outcome of this study may have important implications. First, we propose the 
inclusion of the presence of large invasive cribriform in pathology reports. Of 26 men with large 
cribriform architecture who had undergone pelvic lymph node dissection at time of radical 
prostatectomy, 23% (n=6) had lymph node metastasis. Men with large cribriform architecture 
should therefore not be considered for surveillance but instead be offered active treatment with 
lymph node dissection. On the other hand, the absence of metastasis and low risk of biochemical 
recurrence in Grade Group 2 patients with no cribriform architecture might indicate that active 
surveillance can be considered in these men, and that pelvic lymph node dissection might be 
omitted when treatment is offered. However, it is important to note that the current results were 
obtained after studying radical prostatectomy specimens, while treatment decisions are made 
based on diagnostic biopsies. An urgent need exists to incorporate pathological features such as 
small and large invasive cribriform growth, as well as intraductal carcinoma, into clinical 
nomograms and prediction tools. 
Strong points of this study are the detailed histological review and the extensive 
immunohistochemical staining for classification of cribriform architecture. Although large 
cribriform growth is an adverse predictive parameter for Grade Group 2 prostate cancer patients, 
the stringent cut-off used in this study resulted in the inclusion of a relatively small number of cases 
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and must be validated. Finally, the retrospective study design and relatively short median follow-
up of 53 months possibly gave rise to a selection bias. 
In conclusion, we demonstrate that patients with large invasive cribriform growth 
represent a more aggressive subgroup of cribriform Grade Group 2 prostate cancer. Men with large 
invasive cribriform carcinoma should be actively treated since they are at increased risk for 


















Concordance of cribriform architecture in matched prostate 
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Invasive cribriform and/or intraductal carcinoma have been identified as independent adverse 
parameters for prostate cancer outcome. Little is known on biopsy undersampling of cribriform 
architecture. Our aim was to determine the extent of cribriform architecture undersampling and 
to find predictive factors for identifying false cribriform negative cases.  
We reviewed 186 matched prostate biopsies and radical prostatectomy specimens. Of 97 
biopsy Grade Group 2 (Gleason score 3+4=7) patients, 22 (23%) had true cribriform negative 
(TN), 39 (40%) false negative (FN) and 36 (37%) true positive (TP) biopsies. Patients with FN 
biopsies had higher albeit not statistically significant (P=0.06) median PSA levels than patients 
with TP biopsies (12 versus 8 ng/ml). A PI-RADS 5 lesion was present in 9/16 (54%) FN and 3/11 
(27%) TN biopsies (P=0.05). Positive biopsy rate (P=0.47), percentage Gleason pattern 4 (P=0.55) 
and glomeruloid architecture (P=1.0) were not different. Logistic regression identified PSA as 
independent predictor (Odds Ratio 3.5; 95% Confidence Interval 1.2-9.4, P=0.02) for cribriform 
architecture on radical prostatectomy but not PI-RADS score. The FN rate for large cribriform 
architecture at radical prostatectomy was 27%, which was lower than for any cribriform 
architecture (P=0.01). During follow-up (median 27 months), biochemical recurrence-free survival 
of patients with TP biopsies was significantly shorter than of those with FN biopsies (P=0.03). 
In conclusion, 40% of Grade Group 2 prostate cancer biopsies were FN for cribriform 
architecture. These patients had higher PSA levels and more frequent PI-RADS score 5 lesions 










Risk stratification and therapeutic decision-making in prostate cancer patients is affected by 
potential biopsy undersampling. The Gleason score is one of the most important parameters for 
predicting disease outcome and guiding individual treatment. Men with Gleason score 3+3=6 
(International Society of Urological Pathology (ISUP) Grade Group 1) prostate cancer are eligible 
for active surveillance, whereas men with Gleason score ≥ 4+3=7 (Grade Group 3-5) are usually 
treated with radical prostatectomy, radiation therapy and/or hormonal therapy. The optimal 
therapeutic strategy for men with Gleason score 3+4=7 (Grade Group 2) still is a matter of debate. 
While most of these patients will undergo active treatment, surveillance is increasingly being 
considered in this subgroup. Incorporation of additional clinicopathological and molecular 
parameters might be able to support optimal decision-making in this large prostate cancer 
subpopulation. 
Grade Group 2 prostate cancer is a heterogeneous disease with variable architectural 
growth patterns and Gleason pattern 4 quantities. While individual growth patterns are not 
routinely mentioned in pathology reports, recent studies have shown that patients with cribriform 
architecture have adverse outcome as compared to those without.15, 39, 50 Both invasive and 
intraductal cribriform architecture have been associated with adverse clinicopathological 
characteristics, post-operative recurrence rates, metastasis and disease-specific death.14, 16, 32, 34, 51 
On the other hand, biopsy Grade Group 2 prostate cancer patients without cribriform architecture 
have comparable disease-specific survival and post-operative biochemical recurrence rates as men 
with Grade Group 1 disease.39, 52 Quantification of Gleason pattern 4 can further add in risk 
stratification since post-operative biochemical recurrence rates increment with higher Gleason 
pattern 4 tumour percentage.53 Cribriform architecture and Gleason pattern 4 quantification might 
therefore be important adjuncts in risk stratification of Grade Group 2 prostate cancer patients. 
While pathological tumour characteristics are important for clinical decision-making, 
prostate biopsies are prone to undersampling. Prostate cancer is upgraded in up to 40% of 
subsequent radical prostatectomy specimens.54, 55 At present, little is known on the extent of 
undersampling in detection of cribriform architecture or Gleason pattern 4 percentage. The aim of 
our study is to determine the extent of undersampling for the detection of cribriform architecture 
in matched prostate biopsy and radical prostatectomy specimens, and to identify potential factors 
for discriminating true from false cribriform negative prostate biopsies. 
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Materials and Methods 
 
Patient selection 
We identified 186 patients who had undergone both biopsy and subsequent radical prostatectomy 
at Erasmus MC University Medical Center, Rotterdam, The Netherlands between 2010 and 2017. 
Biopsies were prompted by elevated Prostate Specific Antigen (PSA) levels or obtained in the 
scope of active surveillance. The Prostate Imaging Reporting and Data System (PI-RADS) score 
was annotated by an expert uroradiologist, when patients had received multiparametric magnetic 
resonance imaging (MRI).56 When suspicious lesions (PI-RADS 3 to 5) were visible on MRI, 
targeted MRI-ultrasound fusion biopsies were taken. Individual biopsy cores were enclosed in 
separate containers and radical prostatectomy specimens were completely embedded for 
diagnostic purposes. All slides of both biopsies and radical prostatectomies were available for 




All biopsies were reviewed by three investigators, who were blinded to clinical outcome and 
radical prostatectomy characteristics. For each biopsy core the following features were recorded: 
Gleason score, Grade Groups according to the WHO/ISUP 2014 guidelines, maximal single 
biopsy tumour length (mm), overall estimated percentage Gleason pattern 4 and individual 
tumour growth patterns.12 Invasive cribriform Gleason pattern 4 was not distinguished from 
intraductal carcinoma because of their significant morphological overlap, which would require 
extensive immunohistochemical staining for further discrimination.39 In case targeted biopsies 
were obtained, these were considered as separate biopsies and not as one single biopsy. Matching 
radical prostatectomy specimens were evaluated as described previously.51 We recorded Gleason 
score, Grade Group, pT-stage according to the AJCC TNM 8th edition, surgical margin status, 
percentage Gleason pattern 4 and individual growth patterns.41 Furthermore, we distinguished 
small and large expansive cribriform growth pattern based on a cut-off of two times the size of 
adjacent pre-existent normal glands.51  
 
Clinical follow-up 
After radical prostatectomy, clinical follow-up consisted of bi-annual, and later annual monitoring 
of serum PSA levels. Biochemical recurrence was defined as PSA levels ≥ 0.2 ng/ml measured at 
two consecutive points in time, at least three months apart with undetectable PSA levels after 




operation. Survival was defined as time in months from radical prostatectomy to biochemical 
recurrence or last follow-up. 
 
Statistical analysis 
Continuous variables with normal distribution were compared by Student’s t-test and One-way 
ANOVA analysis, those without normal distribution with the Mann-Whitney U test. For 
categorical parameters Chi-square or Fishers exact were used. Correlation between continuous 
variables was analysed using Pearson’s correlation coefficient. Dichotomous outcome variables 
were analysed using logistic regression. Survival was visualised by Kaplan-Meier curves. Statistics 
were performed using R version 3.2.2 (R, Vienna, Austria) and results were considered significant 









The entire cohort consisted of 186 patients with matched biopsy and radical prostatectomy 
specimens. The mean age at time of operation was 65 years (interquartile range (IQR) 62-70) and 
the mean PSA level was 12 ng/ml (IQR 6-15). In total 144 (77%) patients underwent systematic 
biopsies, 26 (14%) received systematic and targeted biopsies, and 16 (9%) had targeted biopsies 
only. The mean number of biopsies taken was 9 (IQR 8-10) with 4 (IQR 3-5) biopsies containing 
adenocarcinoma, representing 49% (IQR 30-66) of the total number of biopsy cores. Fifty (27%) 
patients had overall biopsy Grade Group 1, 99 (53%) Grade Group 2, 11 (6%) Grade Group 3, 15 
(8%) Grade Group 4 and 11 (6%) Grade Group 5. 
On radical prostatectomy, 87 (47%) adenocarcinomas were pT2, 76 (41%) pT3a and 23 
(12%) pT3b. Distribution of the Grade Groups on radical prostatectomy was as follows: 19 (10%) 
Grade Group 1, 108 (58%) Grade Group 2, 25 (14%) Grade Group 3, 17 (9%) Grade Group 4 and 
17 (9%) Grade Group 5. Tumour upgrading occurred in 65 (35%) and down-grading in 14 (8%) 
radical prostatectomies, while 107 (57%) cases had concordant tumour grades. Positive surgical 
margins were present in 63 (34%) patients. Eighty patients had simultaneously undergone pelvic 
lymph node dissection, of which 18 (23%) contained lymph node metastasis. The mean post-
operative follow-up was 32 months (median 22, IQR 8-51). 
Invasive cribriform and/or intraductal carcinoma was observed in 57 (31%) diagnostic 
biopsies and in 128 (69%) radical prostatectomy specimens (Table 3.1). Cribriform architecture 
was present in both matched biopsy and radical prostatectomy specimens in 55 (30%), and absent 
in 56 (30%) cases. In 73 (39%) men cribriform architecture was observed in the radical 
prostatectomy specimen, but not in preceding biopsies. Two cases (1%) with cribriform 
architecture at biopsy but not at subsequent radical prostatectomy, probably due to sampling error, 
were excluded from further analyses. Therefore, sensitivity for cribriform architecture on biopsies 
was 43%, while specificity was 97%. Cribriform architecture was observed more frequently in 
targeted (19/40; 48%) than systematic biopsies (36/144; 25%, P=0.01). 
 
Table 3.1. Prevalence of invasive cribriform and/or intraductal carcinoma (CR/IDC) in biopsies 
and matched radical prostatectomies. 
 Radical prostatectomy 
Prostate biopsy CR/IDC- CR/IDC+ 
CR/IDC- 56 (30%) 73 (39%) 




Concordance of cribriform architecture in Grade Group 2 prostate cancer biopsies  
Since cribriform architecture might be most relevant for treatment decisions in patients with biopsy 
Grade Group 2 prostate cancer, we performed further analyses within this subgroup (n=97). Thirty 
six (37%) patients with biopsy Grade Group 2 demonstrated cribriform architecture on both 
matched biopsy and radical prostatectomy specimen (true cribriform positive, CR+/CR+), while 
cribriform architecture was absent in both specimens in 22 (23%) cases (true cribriform negative, 
CR-/CR-). In 39 (40%) patients cribriform architecture was present on radical prostatectomy but 
not on preceding biopsy; these patients were considered as having false cribriform negative (CR-
/CR+) biopsies. None of the patients with biopsy Grade Group 2 had cribriform architecture on 
biopsy while radical prostatectomy was negative for cribriform architecture. 
 
Identification of predictors in true and false cribriform negative Grade Group 2 prostate cancer biopsies 
Patients with true negative biopsies were slightly younger (62 versus 65 years, P=0.06) and had 
lower PSA levels (8 ng/ml versus 12 ng/ml, P=0.06) than men with false negative biopsies, 
however these differences were not significant (Table 3.2). In total, 51 patients (53%) had 
undergone multiparametric MRI prior to biopsy. Out of 11 patients with true negative biopsies, 3 
(27%) had a PI-RADS 5 lesion as compared to 9/16 (56%) of false negative and 17/24 (71%) of 
true positive biopsy patients (P=0.05). The number of biopsies (P=0.53), percentage of positive 
biopsies (P=0.47) and maximal tumour length (P=0.44) were not different between true and false 
negative biopsies.  
Since Gleason pattern 4 percentage and glomeruloid architecture have both been 
associated with cribriform architecture, we assessed the predictive value of these pathologic 
parameters.16, 19 Mean percentage of Gleason pattern 4 was 12% (IQR 5-10%) in true negative 
biopsies and 11% (IQR 5-16%) in false negative biopsies (P=0.55). There was only a weak 
correlation between percentage Gleason pattern 4 on biopsies (mean 13%, IQR 5-20%) and 
matched radical prostatectomies (mean 31%, IQR 10-40%, R2=0.093; P=0.001). Glomeruloid 
growth pattern was encountered in 6/22 (27%) true negative and 11/39 (28%) false negative 
biopsies (P=1.0). 
Logistic regression analysis on cribriform negative biopsy patients showed that age (odds 
ratio (OR) 1.1, 95% confidence interval (CI) 1.0-1.3, P=0.02) and PSA (OR 3.3, 95% CI 1.2-9.1, 
P=0.02) were independent predictive parameters for presence of cribriform architecture on radical 
prostatectomy in multivariable analysis, whereas PI-RADS score, number and percentage of 
positive biopsies, maximal tumour length, presence of targeted biopsies and percentage Gleason 
grade 4 were not (Table 3.3).  
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Table 3.2. Characteristics of biopsy Grade Group 2 prostate cancer (PCa) patients stratified for 
true cribriform negative (CR-/CR-), false cribriform negative (CR-/CR+) and true cribriform 
positive (CR+/CR+) biopsies. 
 CR-/CR- (n=22) CR-/CR+ (n=39) CR+/CR+ (n=36) P-value 
Age 62 (63, 58-65) 65 (66, 62-71) 66 (66, 62-71) 0.06a 
PSA 8 (8, 6-10) 12 (10, 6-17) 16 (13, 9-19) 0.06b 
PI-RADS score: no MRI 11 (50%) 23 (59%) 12 (33%) 0.10c 
   1-2 3 (14%) 0 (0%) 0 (0%)  
   3 1 (5%) 1 (3%) 2 (6%)  
   4 4 (18%) 6 (15%) 5 (14%)  
   5 3 (14%) 9 (23%) 17 (47%)  
Number of biopsies 9 (9, 8-10) 8 (8, 7-10) 10 (10, 8-12) 0.53d 
# PCa positive biopsies 4 (3, 2-6) 4 (4, 3-5) 6 (5, 4-8) 0.64d 
% PCa positive biopsies 47 (38, 25-71) 52 (50, 31-73) 59 (61, 40-76) 0.47d 
Max tumour length (mm) 7 (7, 5-8) 8 (7, 5-10) 9 (10, 7-12) 0.44d 
% Gleason pattern 4 12 (8, 5-10) 11 (8, 5-16) 17 (15, 7-23) 0.55a 
Glomeruloid growth 6 (27%) 11 (28%) 12 (33%) 1.0e 
Large cribriform growth 0 6 (15%) 16 (44%) N/A 
Targeted biopsies 2 (9%) 8 (20%) 13 (36%) 0.30e 
Grade Group (RP): 1 2 (9%) 1 (3%) 1 (3%) 0.01e 
   2 18 (82%) 29 (74%) 26 (72%)  
   3 0 (0%) 8 (20%) 7 (19%)  
   4 0 (0%) 1 (3%) 1 (3%)  
   5 2 (9%) 0 (0%) 1 (3%)  
Positive surgical margins 8 (36%) 12 (31%) 12 (33%) 0.78c 
pT stage (TNM 8th ): 2 11 (50%) 15 (38%) 17 (47%) 0.66c 
   3a 10 (45%) 20 (51%) 12 (33%)  
   3b 1 (5%) 4 (11%) 7 (20%)  
Biochemical recurrence 2 (9%) 6 (15%) 13 (36%) 0.69e 
Metastasis 0 (0%) 1 (3%) 4 (11%) N/A 
Mean (median, IQR) or n (%). a Wilcox-test, b t-test (log2 values were used for this test), c Chi-square (χ2), d 





Table 3.3. Logistic regression analysis of biopsy Grade Group 2 cribriform negative prostate 
cancer (PCa) patients (n=61), predicting cribriform architecture on radical prostatectomy. 
 Univariate  Multivariable 
 OR 95% CI P-value  OR 95% CI P-value 
Age 1.1 1.0-1.2 0.06  1.1 1.0-1.3 0.02 
PSA (log2) 2.2a 1.0-4.8 0.04  3.3
a 1.2-9.1 0.02 
PI-RADS score        
   <5 ref       
   5 1.9 0.5-7.9 0.38  1.8 0.3-9.1 0.49 
Number of biopsies 0.9 0.8-1.1 0.53  0.8 0.6-1.1 0.21 
Percentage PCa positive biopsies  2.1 0.3-15 0.47  0.2 0.0-5.5 0.35 
Maximal tumour length (mm) 1.1 0.9-1.2 0.43  1.0 0.9-1.3 0.70 
Percentage Gleason pattern 4  1.0 0.9-1.0 0.70  1.0 0.9-1.0 0.36 
Presence of targeted biopsies        
   No ref       
   Yes 2.6 0.5-13 0.26  1.1 0.1-10 0.91 
a Per doubling unit. OR = odds ratio, CI = confidence interval. 
 
 
Figure 3.1. Biochemical recurrence-free survival of biopsy Grade Group 2 prostate cancer 
patients, stratified for the presence of cribriform architecture on biopsies and subsequent radical 
prostatectomies (log rank over all groups, P-value = 0.02). 
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Comparison of false negative and true cribriform positive Grade Group 2 biopsies 
PSA levels of men with true positive biopsies were slightly higher than of those with false negative 
biopsies, but this was not statistically significant (16 ng/ml versus 12 ng/ml, P=0.13). Patients with 
true positive biopsies had a significantly higher total number of biopsies (10 versus 8, P=0.02) and 
number of tumour positive biopsies (6 versus 4, P=0.001), however no differences were seen in 
percentage positive biopsies (59% versus 52%, P=0.19) when compared to patients with false 
negative biopsies. Percentage Gleason pattern 4 was higher in patients with cribriform positive 
biopsies than in those with false negative biopsies (17% versus 11%, P=0.03). Final Grade Group 
(P=0.97), pT stage (P=0.27) and surgical margin status (P=0.24) of the radical prostatectomy 
specimens were not different between these two groups. The tumour volume percentage of 
cribriform growth at radical prostatectomy was higher in patients with true positive biopsies than 
in those with false negative biopsies, but this did not meet conventional measures of significance 
(13% versus 6%, P=0.06).  
Large expansile cribriform architecture, which represents an aggressive subtype of 
invasive cribriform carcinoma, was present in 22/97 (23%) radical prostatectomy specimens.51 
Sixteen of these 22 (73%) patients had any size cribriform fields on biopsy, while biopsies were 
false negative in 6 (27%) men. The false negative rate for more aggressive large cribriform 
architecture (6/22; 27%) was lower than for any cribriform architecture (39/75; 52%, P=0.01). In 
case large cribriform carcinoma was present at radical prostatectomy, the tumour volume 
percentage of any cribriform growth at the operation specimens did not differ between men with 
false cribriform negative and true positive biopsies (P=0.5). This indicates that the lower false 
negative rate of large cribriform growth was not merely due to larger total cribriform tumour 
percentage at radical prostatectomy.  
 
Clinicopathological outcome in Grade Group 2 patients 
Of 97 patients with biopsy Grade Group 2 prostate cancer, 73 (75%) had concordant Grade Group 
at radical prostatectomy, 20 (21%) were upgraded to Grade Group 3 to 5, and 4 (4%) down-graded 
to Grade Group 1. Upgrading occurred in 9/36 (25%) true positive and in 9/39 (23%) false 
negative biopsies, and was significantly lower (P=0.01) in true negative biopsies (2/22, 9%). Extra-
prostatic expansion and surgical margins status were not significantly different between the three 
groups. 
Biochemical recurrence occurred in 21 (22%) patients and was significantly more 
frequent in the true positive (13/36, 36%) than in the false negative group (6/39, 15%, P=0.03). 
The true negative group (2/22, 9%) showed the lowest incidence of biochemical recurrence, 




The median post-operative follow-up of Grade Group 2 patients was 27 months (mean 
18, IQR 6-40). Patients experienced biochemical recurrence after a median of 14 months (mean 
24, IQR 5-32). Biochemical recurrence-free survival was not significantly different between 
patients with true negative and false negative biopsies (log rank P=0.55). Patients with cribriform 
positive biopsies had significantly shorter biochemical recurrence-free survival than men with false 






Identification and pathologic reporting of invasive cribriform and/or intraductal carcinoma of the 
prostate are increasingly important since they are both associated with adverse clinical outcome.14, 
34, 39, 50 Biopsy undersampling is a well-known problem which might have significant impact on 
individual patient management.54, 57, 58 Hitherto, little is known about biopsy undersampling in 
identifying cribriform architecture. In this study we demonstrated that biopsies were false negative 
for cribriform architecture in 39% of all cases and in 40% of patients with biopsy Grade Group 2 
prostate cancer. In false negative Grade Group 2 patients, age and PSA level were independent 
predictive parameters for presence of cribriform architecture on subsequent radical prostatectomy, 
while percentage of positive biopsies, maximal biopsy tumour length, percentage Gleason pattern 
4 and glomeruloid growth were not. Patients with the more aggressive large cribriform growth 
pattern on radical prostatectomy were, however, less likely to have cribriform negative biopsies.51 
Biopsy Grade Group 2 patients with false cribriform negative biopsies showed better biochemical 
recurrence-free survival rates than men with true cribriform positive biopsies albeit follow-up was 
relatively short. 
Masoomian et al. studied concordance rates of cribriform architecture in 245 matched 
biopsies and operation specimens, and found a relatively low sensitivity of 47%, corresponding 
well with the 43% sensitivity in our study.59 In their subset of Grade Group 2 biopsy patients, false 
negative and true positive biopsies both had more advanced stage as compared to true negative 
biopsies on radical prostatectomy suggesting men with false negative and true positive biopsies 
have comparable outcome. This contrasts with our study as we found that post-operative 
biochemical recurrence-free survival of men with true positive biopsies was significantly shorter 
than of those with false negative biopsies. The difference might be explained by the different and 
relatively small cohorts of both studies. 
 While most patients with biopsy Grade Group 2 prostate cancer undergo active 
treatment, the question is rising whether surveillance could be a safe alternative for subgroups of 
this large patient population. It has for instance been proposed that patients with biopsy Grade 
Group 2 prostate cancer and low Gleason pattern 4 percentage should be considered for 
surveillance.44, 60 Others have suggested that biopsy Grade Group 2 prostate cancer patients 
without invasive cribriform and/or intraductal carcinoma might be eligible for surveillance.32, 52 
To further support clinical decision tools, it is important to get insight in the false negative rate of 
potentially aggressive disease parameters and to determine how this rate can be minimised to an 
acceptable level. In the current study, we showed that consideration of PSA level, which is an 




negative biopsies from being abstained from immediate treatment. Furthermore, presence of a PI-
RADS 5 lesion on multiparametric MRI might also be indicative of more aggressive disease. 
Truong et al. identified cribriform morphology in combined systematic and targeted biopsies in 
37% of PI-RADS 5, 24% of PI-RADS 4 and 6% of PI-RADS 2 lesions, suggesting that high-grade 
MRI lesions are related to more aggressive tumours with cribriform morphology.48 Prendeville et 
al. identified cribriform morphology in 8% of PI-RADS 3/4 lesions and in 39% of PI-RADS 5 
lesions, indicating that PI-RADS score might be a predictor for cribriform positive prostate 
cancer.49 Here we showed that 56% of false negative biopsies had a PI-RADS 5 lesion as compared 
to 27% of true negative biopsies. However, due to the small number of patients that had undergone 
MRI, PI-RADS score was not a predictor for cribriform architecture in logistic regression analysis. 
We were not able to find any predictive value of biopsy percentage Gleason pattern 4 or 
glomeruloid growth pattern for cribriform architecture on radical prostatectomy. Presence of 
cribriform architecture has been associated with higher percentage Gleason pattern 4 on biopsies. 
In a cohort of 370 biopsy Grade Group 2 prostate cancer patients, we found cribriform architecture 
in 6% of men with <10% Gleason pattern 4, in 22% of men with 10-25% pattern 4, and in 44% of 
men with 25-50% pattern 4.32 Nevertheless, biopsy percentage Gleason pattern 4 was not 
predictive for cribriform architecture in false negative biopsies. This paradoxical outcome could 
be explained by the low level of concordance between percentage Gleason pattern 4 on biopsy and 
matched radical prostatectomy specimens in this study. Similarly, glomeruloid Gleason pattern 4 
which has been hypothesised to represent a precursor lesion of cribriform growth, was not 
associated with cribriform architecture in false negative biopsies.19 
Amongst patients with cribriform architecture, those with large expansive cribriform 
fields have the worst outcome.51 The false negative rate of 27% for large cribriform pattern is 
significantly less than the rate of 52% for overall cribriform morphology. Since 44% of true positive 
biopsies had large cribriform fields on radical prostatectomy as compared to only 15% of false 
negative biopsies, this might explain the significantly better biochemical recurrence-free survival 
of false negative biopsies as compared to true positive biopsies, in addition to other 
clinicopathological confounding factors. 
The strong points of this study are the detailed histological review of matched biopsies 
and radical prostatectomies. The study is however limited by its low number of patients, the 
heterogeneity of the study population including both patients with first-time diagnosis and 
progression during active surveillance, and variability of diagnostic work-up encompassing 
systematic and/or targeted biopsies as well as multiparametric MRI assessment. Finally, follow-
up is relatively short with a median of 27 months. 
45 
In conclusion, we demonstrate that 40% of men with biopsy Grade Group 2 prostate 
cancer were false negative for invasive cribriform and/or intraductal carcinoma. Age and PSA 
were independent predictors for cribriform architecture in false negative biopsies, while patients 
with false negative biopsies more frequently had PI-RADS score 5 lesions than men with true 
negative biopsies. Multimodal evaluation of biopsy Grade Group 2 prostate cancer patients could 


















Clinical outcome comparison of Grade Group 1 and Grade 
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Invasive cribriform and intraductal carcinoma are associated with aggressive disease in Grade 
Group 2 (GG2) prostate cancer patients. However, the characteristics and clinical outcome of 
Grade Group 2 patients without cribriform architecture (GG2-) compared to those with Grade 
Group 1 (GG1) disease are unknown. The aim of this study was to investigate the clinical and 
pathological characteristics of GG1 and GG2- prostate cancer in radical prostatectomy specimens.  
We reviewed 835 radical prostatectomy specimens for Grade Group, pT-stage, surgical margin 
status and presence of cribriform architecture. Biochemical recurrence-free survival and metastasis 
were used as clinical outcomes. GG1 prostate cancer was seen in 207 and GG2 in 420 patients, of 
whom 228 (54%) showed cribriform architecture (GG2+) and 192 (46%) did not. Patients with 
GG2- disease had higher Prostate Specific Antigen levels (9.4 versus 7.0 ng/ml; P<0.001), more 
often extra-prostatic extension (36% versus 11%; P<0.001) and more frequent positive surgical 
margins (27% versus 17%; P=0.01) than those with GG1. GG2- patients had shorter biochemical 
recurrence-free survival (Hazard Ratio (HR) 2.7, 95% Confidence Interval (CI) 1.4-4.9; P=0.002) 
than those with GG1. Lymph node and distant metastasis were neither observed in GG2- nor in 
GG1 patients, but occurred in 22/228 (10%) of GG2+ patients.  
In conclusion, patients with GG2- prostate cancer at radical prostatectomy have more advanced 
disease and shorter biochemical recurrence-free survival than men with GG1, but both groups 







Active surveillance is increasingly applied in men with prostate cancer. Whereas most men with 
biopsy Grade Group 1 (Gleason score 3+3=6, GG1) prostate cancer are eligible for active 
surveillance, inclusion of favourable Grade Group 2 (Gleason score 3+4=7, GG2) patients with 
limited Gleason pattern 4 is gradually accepted.45, 61-64 In general, these patients have Prostate 
Specific Antigen (PSA) levels of <10 ng/ml, present with organ-confined disease and have <10% 
Gleason pattern 4 in their diagnostic biopsies.7 
Gleason pattern 4 prostate cancer is a heterogeneous disease encompassing various 
histopathological growth patterns. Invasive and/or intraductal cribriform carcinoma, both also 
referred to as cribriform architecture, have been identified as pathological parameters for worse 
outcome in both biopsy as well as radical prostatectomy specimens.13-17, 34 Cribriform architecture 
has been associated with advanced tumour stage, biochemical recurrence, metastasis and disease-
specific death in GG2 prostate cancer.32, 50, 51 While patients with GG2 prostate cancer without 
cribriform architecture (GG2-) have favourable outcome compared to those with invasive and/or 
intraductal cribriform carcinoma (GG2+), it is unclear to what extent GG2- differs from GG1 
disease. 
In previous sextant biopsy studies with long-term follow-up, patients with biopsy GG2- 
prostate cancer had similar biochemical recurrence-free and disease-specific survival as men with 
GG1 disease.39, 52 Therefore, it has been proposed that patients without cribriform architecture 
might be eligible for active surveillance.32, 39, 44, 52, 60, 65 Prostate biopsies are, however, subject to 
significant sampling errors with tumour undergrading in up to 40% and there is low sensitivity for 
detection of cribriform architecture.58, 59, 66 Moreover, in contrast to radical prostatectomy 
specimens, minor high-grade patterns are always taken into account when grading prostate cancer 
biopsies. To elucidate on its clinical and biological features, GG2- prostate cancer should be 
investigated on radical prostatectomy specimens, which excludes study bias by biopsy sampling 
artefacts. The aim of this study was to compare the clinicopathological characteristics and 





Materials and methods 
 
Patient selection 
In total, 854 men who had undergone radical prostatectomy for prostate adenocarcinoma at 
Erasmus MC, University Medical Center, Rotterdam, The Netherlands between 2000 and 2017 
were included. Men who had received hormonal, radiation or viral therapy (n=19) prior to 
operation were excluded from this study.40 After fixation in neutral-buffered formalin, radical 
prostatectomy specimens were sectioned transversely and totally embedded for diagnostic 
purposes. All slides were available for pathology review. The use of tissue samples for scientific 




All 835 radical prostatectomy specimens were reviewed by two investigators (EH, GvL), who were 
blinded to clinical outcome. The following features were recorded: Gleason score and Grade 
Group according to the World Health Organization (WHO) 2016 guidelines, pT-stage according 
to the American Joint Committee on cancer (AJCC) TNM 8th edition, surgical margin status, 
Gleason pattern 3 to 5 percentages, Gleason 4 growth patterns and presence of intraductal 
carcinoma.12, 38, 41 Intraductal carcinoma was not incorporated in the Gleason score. Tertiary 
Gleason patterns occupied less than 5% of the total tumour area and were not incorporated in the 
Gleason score.12, 38  
In order to most accurately distinguish intraductal form invasive cribriform carcinoma, the 
following criteria were used. Invasive cribriform Gleason grade 4 was morphologically 
distinguished from intraductal carcinoma when it had an irregular outline, anastomosing fields 
beyond pre-existent gland architecture or extension into periprostatic fat tissue, ejaculatory ducts 
or seminal vesicles. Intraductal carcinoma was morphologically identified if cribriform structures 
were clearly continuous with pre-existent glands lined by normal basal epithelium, or containing 
corpora amylacea. When invasive cribriform carcinoma and intraductal carcinoma could not be 
differentiated by morphological criteria alone, additional immunohistochemical staining for the 
presence of basal cells was performed. 
 
Immunohistochemistry 
Four micrometer thick tissue sections were cut from selected paraffin-embedded blocks (Superfrost 
Microscopic Slides, ThermoFisher Scientific, Bleiswijk). Slides were deparaffinized and 




and heat-induced antigen retrieval accomplished by 15 min in Tris-EDTA buffer (pH 9; Klinipath, 
Duiven, The Netherlands). Mouse monoclonal high molecular weight cytokeratin (clone 34BE12; 
1:200; DAKO; Heverlee, Belgium) diluted in normal antibody diluent (APG-500; ScyTek 
Laboratories, West Logan, USA) was incubated for 2 hours at room temperature. Antibody 
visualization was performed using the Envision kit (DAKO) and slide counterstaining with 
hematoxylin. When basal cell staining was absent, the cribriform structure was categorized as 
invasive carcinoma; if sporadic, scattered or continuous basal cells were identified the growth 
pattern was classified as intraductal carcinoma.  
 
Clinical follow-up 
Clinical follow-up after radical prostatectomy consisted of six-monthly, and later annual 
monitoring of serum PSA levels. Biochemical recurrence was defined as PSA level ≥ 0.2 ng/ml 
measured at two separate points in time at least three months apart when PSA had been 
undetectable after operation, or as PSA increase of > 2.0 ng/ml whenever serum PSA had not 
declined to zero after operation. Post-operative lymph node and distant metastases were confirmed 
by biopsy or multidisciplinary consensus. Biochemical recurrence-free survival was defined as time 
in months from radical prostatectomy to biochemical recurrence. 
 
Statistical analysis 
Normally distributed, continuous variables were analysed using the independent sample Student’s 
t-test. Pearson’s chi squared (χ2) test was used for categorical parameters. Missing PSA values 
(n=27) were imputed using the median PSA value. Biochemical recurrence-free survival was 
analysed using Cox proportional hazards regression and visualized by Kaplan-Meier curves. 
Statistics were performed using SPSS version 24 (IBM, Chicago, IL, USA). Results were 





Out of 835 radical prostatectomy specimens, 207 had GG1 and 420 GG2 prostate cancer. The 
median age of these 627 patients at time of operation was 64.1 years (interquartile range (IQR) 
59.8-67.6 years) and the median PSA level was 7.6 ng/ml (IQR 5.4-10.8 ng/ml). Pathologic 
tumour stage was distributed as follows: 419 (66%) pT2, 173 (28%) pT3a and 35 (6%) pT3b 
tumours. Positive surgical margins were present in 177 (28%) cases. Pelvic lymph node dissection 
was performed in 375 (60%) men, of whom 12 (3%) had lymph node metastasis. 
 
Invasive cribriform and/or intraductal carcinoma 
Among men with GG2 prostate cancer, 228 (54%) had invasive cribriform and/or intraductal 
carcinoma (GG2+) and 192 (46%) did not (GG2-). GG2+ patients had higher PSA levels (12.2 
ng/ml versus 9.4 ng/ml; P=0.006), higher percentage Gleason pattern 4 (24% versus 18%; P<0.001), 
more frequent extra-prostatic extension (pT3; 52% versus 36%; P<0.001), positive surgical margins 
(40% versus 27%; P=0.007) and lymph node metastases (8% versus 0%; P=0.001) than GG2- 
patients. Patients with GG2- presented with higher median PSA levels (9.4 versus 7.0 ng/ml; 
P<0.001), more frequent extra-prostatic extension (36% versus 11%; P<0.001) and positive surgical 
margins (27% versus 17%; P=0.01) than men with GG1 prostate cancer (Table 4.1). None of the 
patients with GG1 or GG2- tumours had metastasis at lymph node dissection. 
 
Tertiary Gleason pattern 4 in Grade Group 1 prostate cancer 
GG1 prostate cancer in radical prostatectomy specimens might by definition contain tertiary high-
grade patterns. To investigate to what extent GG2- disease differed from GG1 with tertiary pattern 
and/or pure GG1, we analysed both GG1 subgroups separately. Tertiary Gleason pattern 4 was 
present in 42 out of 207 (20%) GG1 patients, of whom 9 (4%) had cribriform architecture. Tertiary 
Gleason pattern 5 was observed in only one (0.5%) patient. Men with tertiary Gleason pattern 4 
had higher median PSA levels (8.4 versus 6.6 ng/ml; P=0.01), more frequent extra-prostatic 
extension (41% versus 3%; P<0.001) and positive surgical margins (43% versus 10%; P<0.001) than 
GG1 men without a tertiary pattern. Although GG2- patients had higher percentage Gleason 
pattern 4 (18% versus 3%; P<0.001) and more often tertiary Gleason pattern 5 (9% versus 0.5%; 
P=0.04) than GG1 men with tertiary Gleason pattern 4, PSA levels (9.4 ng/ml versus 8.4 ng/ml; 







The median follow-up of the entire cohort was 59.6 months (IQR 17.5-113.9). Biochemical 
recurrence occurred in 112 (18%) men after a median of 29.9 months (IQR 11.6-55.5). GG2- 
patients had shorter biochemical recurrence-free survival than GG1 patients, while those with 
cribriform and/or intraductal carcinoma had the worst survival outcome (overall log rank, 
P<0.001, Figure 4.1). Biochemical recurrence-free survival of men with GG1 disease with tertiary 
Gleason pattern 4 and GG2- was similar (log rank, P=0.4).  
In univariate Cox regression analysis, PSA level (Hazard Ratio (HR) 1.03, 95% 
Confidence Interval (CI) 1.02-1.04; P<0.001), pT-stage (HR 2.7, 95% CI 1.8-4.1; P<0.001), 
percentage Gleason pattern 4 (HR 1.03, 95% CI 1.02-1.04; P<0.001), tertiary Gleason pattern 5 
(HR 2.4, 95% CI 1.4-4.2; P=0.002), positive surgical margins (HR 3.5, 95% CI 2.4-5.1; P<0.001), 
positive lymph nodes (HR 20.1, 95% CI 9.8-41.5; P<0.001) and Grade Groups were all 
significantly associated with biochemical recurrence-free survival (Table 4.2). In multivariable 
analysis, GG2+ (HR 3.0, 95% CI 1.4-6.3; P=0.004), pT3-stage (HR 1.6, 95% CI 1.0-2.4; P=0.05), 
positive surgical margins (HR 2.3, 95% CI 1.6-3.5; P<0.001) and positive lymph nodes (HR 7.2, 
95% CI 3.0-17.2; P<0.001) had independent predictive value for biochemical recurrence-free 
survival. Although GG2- patients had shorter biochemical recurrence-free survival (HR 1.9, 95% 
CI 0.9-3.8) than GG1 patients, this did not meet conventional measures of significance (P=0.08) 
in multivariate analysis. 
During follow-up, 13 (6%) patients with GG2+ developed distant metastasis, of whom 3 
had positive lymph nodes at time of radical prostatectomy. While in total 22 (10%) patients with 
GG2+ had developed either lymph node or distant metastasis, no metastases were identified in 
any men with GG2- or GG1 prostate cancer at time of operation or during follow-up. Three men 
deceased from prostate cancer, all having GG2+ disease. 
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Table 4.1. Clinicopathological characteristics of prostate cancer patients with Grade Group 1 
(GG1), Grade Group 2 without cribriform architecture (GG2-) and Grade Group 2 patients with 























PSA (ng/ml) 7.0 (6.3; 4.0-9.2) 9.4 (7.7; 5.4-10.5) <0.001 12.2 (8.3; 6.3-
14.0) 
pT-stage 
  T2 
  T3a 
















Gleason pattern 4 (%) 0.6 (0; 0-0) 18 (15; 10-25) <0.001 
 




5 (2%)** 0 0.03 204 (90%) 
Intraductal carcinoma 
 
4 (2%)** 0 0.05 103 (45%) 
Tertiary Gleason pattern 
5 
 
1 (0.5%) 18 (9%) <0.001 31 (14%) 
Positive surgical margin 
status 
 
35 (17%) 52 (27%) 0.014 90 (40%) 
Pelvic lymph node 
dissection 












16 (8%) 29 (15%) 0.02 67 (29%) 
Metastasis 
 
0 0 - 13 (6%) 
Disease-specific death 
 
0 0 - 3 (1%) 
Values represent either mean (median; IQR) or n (%). *P-values represent statistical comparison of GG1 and 





Table 4.2. Cox regression analysis of biochemical recurrence-free survival in patients with Grade 
Group 1 (GG1) and Grade Group 2 prostate cancer patients with (GG2+) and without (GG2-) 
cribriform architecture. 
 
 Univariate analysis Multivariable analysis 


















1.03 1.02 - 1.04 <0.001 1.01 1.00 - 1.02 0.13 
pT-stage 
  T2 
  T3a 








1.8 - 4.1 











1.0 - 2.4 




















20.1 9.8 - 41.5 <0.001 7.2 3.0 - 17.2 <0.001 
Grade Group 
  GG1 
  GG2- 








1.4 - 4.9 











0.9 - 3.8 





HR = hazard ratio, CI = confidence interval. 
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Figure 4.1. Kaplan Meier curves for biochemical recurrence-free survival in Grade Group 1 
(GG1) and Grade Group 2 prostate cancer patients with (GG2+) and without (GG2-) cribriform 









During the last decade, various studies demonstrated that GG2 prostate cancer patients with 
invasive cribriform and/or intraductal carcinoma have worse disease outcome than those 
without.13, 15, 24, 39, 51, 67 Although it is generally accepted that GG2 prostate cancer patients have 
more aggressive disease than men with GG1, it is unclear whether this is still the case when those 
with aggressive cribriform pathology are excluded. In this study, we found that 46% of men with 
GG2 prostate cancer at radical prostatectomy had neither invasive cribriform nor intraductal 
carcinoma. These men had significantly higher PSA levels, pT-stage, positive surgical margin rates 
and shorter biochemical recurrence-free survival than men with GG1 disease. However, none of 
the 399 men with GG1 or GG2- prostate cancer had metastasis at time of operation or during 
follow-up, while metastases were identified in 10% of GG2+ patients. These findings indicate that 
invasive cribriform and/or intraductal carcinoma might have most impact on metastatic disease 
progression. 
Although both invasive cribriform and intraductal carcinoma are pathological features 
associated with tumour aggressiveness, it is yet unclear how to incorporate these parameters in 
clinical risk stratification. For instance, Iczkowski et al. proposed to modify current Grade Groups 
2 to 4 by reporting the presence of invasive cribriform and intraductal carcinoma denoted with a 
“C”, which would increase the risk groups from 5 to 8.68 However, it is not yet evident whether 
clinically relevant differences exist between each of these subgroups or if they partially overlap. 
Previously, our group found that men with GG2- at biopsy had similar biochemical recurrence 
rates and disease-specific survival to men with GG1.32, 39, 52 We currently demonstrate that GG2- 
is associated with significantly worse clinicopathological characteristics and outcome than GG1 
disease. These findings at radical prostatectomy specimens slightly differ from our previous study 
on biopsy specimens52. This might be explained by biopsy sampling artefacts, as upgrading occurs 
in up to 40% of biopsy GG1 and GG2 prostate cancer.61, 69. Furthermore, recent studies indicate 
that biopsies have a moderate sensitivity of 43 to 47% for detecting cribriform architecture.59, 66 
Despite the moderate concordance of growth patterns between biopsy and radical prostatectomy 
evaluation, incorporation of cribriform architecture into the Grade Groups has better 
discriminative value for disease-specific survival and metastasis-free survival.65 In biopsies, we 
previously demonstrated that subtraction of one Grade Group, when cribriform architecture is not 
present, is a simple and valuable modification of the current prostate cancer grading.65 
Metastasis-free survival of GG2- and GG1 disease was similar in both biopsy and radical 
prostatectomy studies.52 GG1 prostate cancer at radical prostatectomy is known to have very low 
if any risk of metastasis and disease-specific death.45, 70-77 Since no metastases were identified in 
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pelvic lymph node dissection or during follow-up of GG2- men, this population seems to have a 
low risk of metastatic progression as well. This indicates that invasive cribriform and intraductal 
carcinoma in particular might have impact on the biological potential of developing metastatic 
disease. In contrast, postoperative biochemical recurrence-free survival is also related to tumour 
volume parameters and surgical technique, which do not necessarily reflect biological 
derangement of the disease. Cribriform architecture has been associated with genomic instability 
and has clonally been related to lymph node metastasis, which might provide a rationale for its 
aggressive biological behaviour.18, 78-80 
Forty-two out of 207 (20%) GG1 patients had a tertiary Gleason pattern 4. These patients 
had worse clinicopathological features than men with pure GG1 disease and were more 
comparable to GG2- patients. This finding is in line with others reporting on the clinical relevance 
of tertiary patterns and underlines the importance of reporting them.81-90  
The strong point of this study is the detailed histological evaluation of the radical 
prostatectomy specimens, including recently identified clinically relevant pathologic parameters. 
Limitations of this retrospective investigation are its relatively low number of patients and limited 
follow-up time of median 59.6 months. Identification of small differences in metastasis-free 
survival would need a large number of low-risk patients with long-term follow-up. 
In conclusion, patients with GG2- prostate cancer at radical prostatectomy have more 
advanced disease and shorter biochemical recurrence-free survival than men with GG1. However, 
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Glomeruloid architecture is the least common Gleason 4 growth pattern in prostate 
adenocarcinoma. Its clinicopathological features and relation with cribriform architecture, which 
has been recognized as an adverse feature, remains to be established. Our objective was to 
investigate clinicopathological features of glomeruloid architecture in radical prostatectomies. 
We reviewed 1064 radical prostatectomy specimens and recorded Grade Group, pT-
stage, margin status, Gleason pattern percentages and growth patterns. Simple and complex 
glomerulations were distinguished by gland size and intraluminal cribriform protrusions. Clinical 
endpoint was biochemical recurrence-free survival. 
Glomerulations were identified in 365 (34%) specimens. In 472 Grade Group 2 patients, 
210 (44%) had simple and 92 (19%) complex glomerulations. Complex glomerulations coincided 
with cribriform architecture more often than simple glomerulations (67% versus 52%; P=0.01). 
Men with simple glomerulations had significantly lower Prostate Specific Antigen (PSA) levels 
(9.7 versus 12.1 ng/ml; P=0.03), percentage Gleason pattern 4 (19% versus 25%; P=0.001), extra-
prostatic extension (34% versus 50%; P=0.01) and positive surgical margins (25% versus 39%; 
P=0.04) than those with cribriform architecture. Extra-prostatic extension (37%) and positive 
surgical margins (30%) in men with complex glomerulations resembled those with simple 
glomeruloid rather than those with cribriform architecture. In multivariate Cox regression analysis 
adjusted for PSA, pT-stage, margin status and lymph node metastases, cribriform architecture had 
independent predictive value for biochemical recurrence-free survival (Hazard Ratio (HR) 1.9; 
95% Confidence Interval (CI) 1.2-2.9; P=0.004), while simple (HR 0.8; 95% CI 0.5-1.2; P=0.26) 
and complex (HR 0.9; 95% CI 0.5-1.6; P=0.67) glomerulations did not.  
Both simple and complex glomeruloid architecture are associated with better outcome 
than cribriform architecture in Grade Group 2 prostate cancer patients. Therefore, glomeruloid 
pattern and particularly complex glomerulations should not be classified as a cribriform growth 






The Gleason score and Grade Group are the most important parameters for clinical outcome in 
prostate cancer patients.8, 12 Gleason pattern 4 is a heterogeneous group of growth patterns 
including poorly formed, fused, glomeruloid and cribriform structures. The clinical importance of 
cribriform architecture in prostate cancer has been well-established in recent years, as it is 
independently associated with disease progression and disease-specific death.13, 15, 16, 28, 34, 51, 91 
Glomeruloid growth pattern consists of dilated malignant glands with intraluminal cribriform 
protrusions, attached to one side of the gland wall, resembling a renal glomerulus.12 In 1998, 
Pacelli et al. first described this growth pattern in relation to tumour grade and stage.92 Cribriform 
and glomeruloid growth patterns are often observed together and some have hypothesized that 
glomeruloid morphology might be a precursor of cribriform architecture.19, 93 However, more 
recent studies indicate that glomeruloid pattern is associated with beneficial histopathological 
features and longer biochemical recurrence-free survival among Gleason score 7 prostate cancer 
patients.16, 20  
Interobserver studies have shown that glomeruloid architecture is one of the most 
reproducible growth patterns in prostate cancer grading.94, 95 While interobserver agreement is 
excellent for small glomeruloid protrusions, no consensus exists on the classification of large 
glomeruloid structures as either glomeruloid or cribriform growth pattern.95 Since some institutes 
use cribriform architecture as threshold for active surveillance in Grade Group 2 prostate cancer, 
distinction between glomeruloid and cribriform growth patterns might have major implications 
for patient management. Therefore, the aim of this study was to investigate the clinicopathological 
features and biochemical recurrence-free survival of prostate cancer patients with glomeruloid 
growth pattern who had undergone radical prostatectomy. 
  
65 
Materials and methods 
 
Patient selection 
Patients who had undergone radical prostatectomy for prostate adenocarcinoma in three medical 
centers in The Netherlands between 2000 and 2017 were included in this study. In total, 854 
patients were operated at Erasmus MC, University Medical Center, Rotterdam. In addition, 
patients from Leiden University Medical Center, Leiden (n=96), and the Netherlands Cancer 
Institute, Amsterdam (n=137) were selected for high-grade morphology (Grade Group 3-5). We 
excluded men who had undergone hormonal, radiation or viral therapy (n=23) prior to 
operation.40 Radical prostatectomy specimens were fixed in neutral-buffered formalin, after which 
they were sectioned transversely and completely embedded for diagnostic evaluation. All slides 
were available for pathology review. This study was approved by the institutional Medical 
Research Ethics Committee (MEC-2018-1614).  
 
Pathologic evaluation 
Radical prostatectomy specimens were reviewed by two investigators (EH, GvL) in common 
sessions, blinded to clinical outcome. For each specimen the following features were recorded: 
Gleason score and Grade Group according to the World Health Organization (WHO) and 
International Society of Urological Pathology (ISUP) 2014 guidelines, pT-stage according to the 
American Joint Committee on Cancer (AJCC) TNM 8th edition, surgical margin status, presence 
of individual growth patterns and intraductal carcinoma, and percentage of Gleason pattern 4 and 
5.12, 41 The following Gleason 4 growth patterns were recognized: poorly formed, fused, 
glomeruloid and cribriform glands.12, 38 Furthermore, we distinguished two subgroups of 
glomeruloid growth pattern based on the architecture of intraluminal protrusions (Figure 5.1). 
Simple glomeruloid architecture was defined as malignant glands with small to medium-sized 
solid intraluminal cell clusters with unilocular connection to the gland wall. Complex glomeruloid 
growth pattern had medium to large-sized intraluminal cribriform protrusions with unilocular 
connection to the gland wall; in some cases the gland wall connection was more extensive. The 
distinction between glomeruloid and cribriform architecture was arbitrarily made by the extent of 
gland wall connection, which occupied at least half of the inner glandular surface in cribriform 
growth and less than half in the glomeruloid pattern. In addition, we distinguished small and large 
cribriform growth patterns, the latter being defined as cribriform structures with a diameter more 
than twice the size of adjacent benign glands. Invasive cribriform Gleason pattern 4 was 
morphologically distinguished from intraductal carcinoma based on the following features: 




existent gland architecture or extension into extra-prostatic tissue. Intraductal carcinoma was 
morphologically identified if cribriform structures were continuous with pre-existent glands or 
contained corpora amylacea. If invasive cribriform carcinoma and intraductal carcinoma could 
not be distinguished by morphological criteria alone, additional basal cell immunohistochemistry 
was performed. Cribriform glands completely lacking basal cell staining were categorized as 
invasive cribriform carcinoma. If basal cells were present sporadically, scattered or continuously, 
the cribriform structures were classified as intraductal carcinoma. Gleason pattern 5 was 
considered as a tertiary pattern if it occupied less than 5% of the total tumour area.12, 31, 38 
Intraductal carcinoma and tertiary patterns were not incorporated in the Gleason score. 
 
Clinical follow-up 
Post-operative clinical follow-up consisted of six-monthly, and later annual monitoring of serum 
Prostate Specific Antigen (PSA) levels. Biochemical recurrence was defined as PSA levels ≥ 0.2 
ng/ml measured at two consecutive points in time, at least three months apart with undetectable 
PSA levels after operation, or as PSA increase of > 2.0 ng/ml when serum PSA had not declined 
to zero after the operation. Post-operative lymph node and distant metastases were confirmed by 
biopsy or multidisciplinary consensus. 
 
Statistical analysis 
Continuous variables with normal distribution were analysed using the independent sample 
Student’s t-test. Pearson’s chi squared (χ2) test was used for categorical parameters. Missing PSA 
values (n=27) were imputed using the median PSA value. Biochemical recurrence-free survival 
and metastasis-free survival were analysed using Cox proportional hazards regression and 
visualized by Kaplan-Meier curves. Statistics were performed using SPSS version 24 (IBM, 




Figure 5.1. Gleason grade 4 cribriform and glomeruloid growth patterns. A. Simple glomeruloid architecture 
with intraluminal cell clusters, 10x. B. Complex glomeruloid architecture with large cribriform proliferations 
protruding into the lumen, 5x. C. Simple glomeruloid architecture with vacuolated cytoplasm, therefore not 
classified as complex glomeruloid architecture, 20x. D. Complex glomeruloid architecture (asterisk) based on 
a gland wall connection that occupies less than half of the inner gland surface, and simple glomeruloid 
architecture (arrows) with a small intraluminal protrusion, 15x. E. Small invasive cribriform carcinoma, 10x. 








General patients characteristics 
The cohort consisted of 1064 men with a median age of 65 years (interquartile range (IQR) 60-68) 
and median serum PSA level of 8.3 ng/ml (IQR 6.0-13.2). Median follow-up was 61 months (IQR 
20-104). The cohort included 207 (20%) men with Grade Group 1, 472 (44%) with Grade Group 
2, 126 (12%) with Grade Group 3, 140 (13%) with Grade Group 4 and 119 (11%) with Grade 
Group 5 prostate cancer. Pathological stage was distributed as follows: 582 (55%) pT2, 334 (31%) 
pT3a, 145 (14%) pT3b and 3 (0.3%) pT4 tumours. Surgical margins were positive in 389 (37%) 
patients. Pelvic lymph node dissection was performed in 664 (62%) patients, of whom 64 (10%) 
had lymph node metastases. 
 
Gleason 4 growth patterns 
Poorly formed and fused glands were observed in 691 (65%) and 613 (58%) men, respectively. 
Invasive cribriform pattern was present in 519 (49%) men, 189 (18%) of whom had large expansive 
growth. Intraductal carcinoma was identified in 314 (30%) specimens. In total, 569 (54%) men 
had invasive cribriform and/or intraductal carcinoma, 190 (33%) of whom had large invasive 
cribriform growth. Glomeruloid growth was the least frequent Gleason 4 pattern, being present in 
365 (34%) men. It was the single Gleason 4 pattern in only 10 (1%) men. Simple glomeruloid 
glands were present in 352 (33%) men and complex glomeruloid glands in 154 (15%) men. Among 
patients with glomeruloid architecture, 211 (58%) had simple glomerulations only, 13 (4%) had 
complex glomerulations only, and 141 (38%) had both simple and complex glomeruloid glands. 
Simple and complex glomeruloid patterns had concomitant invasive and/or intraductal cribriform 
carcinoma in 128/211 (61%) and 121/154 (79%) cases (P<0.001), respectively. Complex 
glomeruloid growth did not coincide more often with large compared to small cribriform growth 
(P=0.26). 
Simple glomerulations were present in 212 (45%) Grade Group 2, 56 (44%) Grade Group 
3, 47 (34%) Grade Group 4 and 28 (24%) Grade Group 5 tumours. In 9 (4%) men with Grade 
Group 1 tumours, simple glomerulations were present as tertiary Gleason pattern 4. Complex 
glomerulations were observed in 92 (19%) men with Grade Group 2, 34 (27%) with Grade Group 
3, 15 (11%) with Grade Group 4 and 13 (11%) with Grade Group 5 tumours. In none of the cases 
with Grade Group 1, complex glomerulations were present as tertiary pattern. Simple and 
complex glomerulations were observed significantly more often in Grade Group 2 and 3 patients 
compared to Grade Group 4 and 5 patients (P=0.05). 
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Table 5.1. Clinicopathological characteristics of Grade Group 2 prostate cancer patients 
categorized for cribriform and/or glomeruloid architecture: men with neither glomeruloid nor 
cribriform architecture (group A), men with simple glomeruloid pattern without complex and/or 
cribriform architecture (group B), men with complex glomeruloid pattern without invasive and/or 
intraductal cribriform carcinoma (group C), and men with invasive and/or intraductal cribriform 
carcinoma regardless of presence of glomerulations (group D). 
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0 0 0 113 (45%) 
Tertiary Gleason 5 
 
13 (10%) 6 (10%) 3 (10%) 35 (14%) 
PSM 
 
35 (27%) 15 (25%) 9 (30%) 97 (39%) 
PLND 













22 (17%) 8 (13%) 4 (13%) 73 (29%) 
Metastasis 
 
0 0 0 17 (7%) 
Disease-specific death 
 
0 0 0 3 (1%) 






Glomeruloid architecture in Grade Group 2 prostate cancer 
Since clinical impact of glomeruloid growth pattern classification is most relevant for Grade Group 
2 prostate cancer patients, we performed further analyses in this subpopulation of 472 men. Of 
these, 216 (46%) had glomerulations: 212 (45%) had simple and 92 (20%) complex glomeruloid 
structures. Simple glomerulations only were present in 124 (57%) men, complex glomerulations 
only in 4 (2%) men, and both patterns occurred concurrently in 88 (41%) cases. Invasive and/or 
intraductal cribriform carcinoma was present in 252 (53%) men with Grade Group 2 prostate 
cancer, 34 (13%) of whom had large invasive cribriform carcinoma. Glomeruloid architecture was 
associated with presence of invasive and/or intraductal cribriform carcinoma, as 126/216 (58%) 
men with glomerulations had coexistent cribriform architecture compared to 126/256 (49%) men 
without glomerulations (P=0.05). Complex glomeruloid structures (62/92, 67%) were more 
frequently concomitant with invasive and/or intraductal cribriform carcinoma than simple 
glomerulations (64/124, 52%, P=0.01). 
Further analyses on glomeruloid and cribriform growth patterns were performed in four subgroups 
(Table 5.1), to investigate the relation between glomeruloid and cribriform architecture. These 
subgroups consisted of men with neither glomeruloid nor cribriform architecture, thus with poorly 
formed and fused glands only (n=130, group A), men with simple glomeruloid pattern without 
complex and/or cribriform architecture (n=60, group B), men with complex glomeruloid pattern 
without invasive and/or intraductal cribriform carcinoma (n=30, group C), and men with invasive 
and/or intraductal cribriform carcinoma regardless of presence of glomerulations (n=252, group 
D). Patients with invasive cribriform and/or intraductal carcinoma (group D) had significantly 
higher percentage Gleason pattern 4 (25% versus 18%; P<0.001), pT-stage (50% versus 36% pT3; 
P=0.003) and positive surgical margin rates (39% versus 27%; P=0.02) than those with poorly 
formed and fused glands only (group A). Men with simple glomerulations (group B) had similar 
PSA levels (9.7 versus 9.1 ng/ml; P=0.6), percentage Gleason pattern 4 (19% versus 18%; P=0.6), 
pT-stage (34% versus 36% pT3; P=0.8), and positive surgical margins (25% versus 27%; P=0.7) to 
men with poorly formed and fused glands only (group A). Compared to men with invasive 
cribriform and/or intraductal carcinoma (group D), men with simple glomerulations (group B) 
had significantly lower PSA levels (9.7 versus 12.1 ng/ml; P=0.03), percentage Gleason pattern 4 
(19% versus 25%; P=0.001), pT-stage (34% versus 50% pT3; P=0.01), and positive surgical margins 
(25% versus 39%; P=0.04). Although men with complex glomeruloid glands only (group C) had 
higher PSA levels (13.1 versus 9.7 ng/ml; P=0.05) than men with simple glomeruloid growth 
pattern (group B), percentage Gleason pattern 4 (20% versus 19%; P=0.6), presence of tertiary 
Gleason pattern 5 (both 10%; P=1.0), pT-stage (37% versus 34% pT3; P=0.8) and surgical margin 
status (30% versus 25%; P=0.6) were similar. Patients with complex glomeruloid glands (group C) 
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had similar PSA levels (13.1 versus 12.1 ng/ml; P=0.7) to those with invasive cribriform and/or 
intraductal carcinoma (group D), but its percentage Gleason pattern 4 was significantly lower (20% 
versus 25%; P=0.04). Although the complex glomeruloid sample size (n=30) was too low for 
reliable statistical analysis, percentage of Gleason pattern 4, presence of tertiary pattern 5, pT-stage 
and positive surgical margin status resembled simple glomerulations (group B) rather than 
cribriform architecture (group D). Among patients with invasive and/or intraductal cribriform 
carcinoma (group D), no significant differences were found in PSA, pT-stage, percentage Gleason 
pattern 4, presence of tertiary Gleason pattern 5 and surgical margin status between those with 
and without glomeruloid architecture (data not shown). 
 
Clinical outcome of Grade Group 2 patients 
Median follow-up of Grade Group 2 patients was 57 months (IQR 14-99). Biochemical recurrence 
occurred in 22/130 (17%) men with poorly formed and fused glands only (group A), in 8/60 (13%) 
men with simple glomerulations (group B), in 4/30 (13%) men with complex glomerulations 
(group C) and in 73/252 (29%) men with cribriform architecture (group D). Survival curves are 
shown in Figure 5.2. No statistically significant difference in biochemical recurrence-free survival 
was found between men with poorly formed and fused glands only (group A), simple glomeruloid 
glands (group B) or complex glomeruloid glands (group C; log rank P=0.38). Patients with 
invasive and/or intraductal cribriform architecture (group D) had significantly shorter biochemical 
recurrence-free survival (log rank P<0.001) than patients with simple (group B, P=0.006) and 
complex glomeruloid glands (group C, P=0.05). 
Cox regression analysis showed that intraductal carcinoma (Hazard ratio (HR) 2.7, 95% 
CI 1.8-4.0, P<0.001), small invasive cribriform carcinoma (HR 1.9, 95% CI 1.3-3.0, P=0.002) and 
large invasive cribriform carcinoma (HR 6.3, 95% CI 3.6-11.1, P<0.001) were associated with 
shorter biochemical recurrence-free survival in univariate analysis (Table 5.2). Adjusted for PSA 
level, pT-stage, surgical margin and pelvic lymph node metastases, large invasive cribriform 
carcinoma remained an independent predictor for biochemical recurrence (HR 3.8, 95% CI 2.1-
6.8, P<0.001) in multivariable analysis. Simple (HR 0.8; 95% CI 0.6-1.4; P=0.64) and complex 
(HR 0.6; 95% CI 0.4-1.2; P=0.19) glomeruloid growth patterns were not associated with 
biochemical recurrence-free survival in univariate or multivariable analysis. Metastases (n=17) 
and disease-specific death (n=3) only occurred in patients with presence of invasive cribriform 






Figure 5.2. Kaplan-Meier curves of biochemical recurrence-free survival in Grade Group 2 
patients with cribriform and/or glomeruloid architecture, stratified for subgroups A to D. 
 
 
Table 5.2. Cox regression analysis for biochemical recurrence-free survival in Grade Group 2 
prostate cancer patients. 
 Univariate  Multivariable 
 HR 95% CI P-value  HR 95% CI P-value 
PSA 1.03 1.01-1.04 <0.001  1.01 1.00-1.02 0.06 
pT-stage        
   T2 ref    ref   
   T3a 1.8 1.2-2.7 0.008  1.5 1.0-2.3 0.07 
   T3b 4.9 2.8-8.5 <0.001  1.9 1.0-3.7 0.07 
Positive surgical margins 2.5 1.7-3.7 <0.001  2.4 1.6-3.7 <0.001 
Pelvic lymph node metastases 15.2 7.6-30.3 <0.001  7.3 3.2-16.8 <0.001 
Intraductal carcinoma 2.7 1.8-4.0 <0.001  1.4 0.9-2.3 0.15 
Invasive cribriform carcinoma        
   Small cribriform 1.9 1.3-3.0 0.002  1.2 0.7-1.8 0.48 
   Large cribriform 6.3 3.6-11.1 <0.001  3.8 2.1-6.8 <0.001 
Glomeruloid growth pattern        
   Simple 0.8 0.5-1.2 0.20  0.8 0.6-1.4 0.64 
   Complex 1.0 0.6-1.6 0.86  0.6 0.4-1.2 0.19 




In this study we investigated the clinicopathological features of glomeruloid Gleason pattern 4 
architecture. Overall glomeruloid architecture was present in 34% of radical prostatectomy 
specimens. In Grade Group 2 patients, simple glomeruloid was seen in 45% and complex 
glomeruloid growth in 20% of men. Men with simple glomeruloid glands only had similar 
clinicopathological characteristics to those with poorly formed and fused glands. Although 
patients with complex glomeruloid glands had higher PSA levels than men with poorly formed, 
fused or simple glomeruloid glands, no significant difference was observed for pT-stage, 
percentage Gleason pattern 4, or biochemical recurrence-free survival. Biochemical recurrence 
and metastasis occurred significantly more often in patients with invasive cribriform and/or 
intraductal carcinoma. Despite their morphological resemblance, men with complex 
glomerulations had better outcome than those with cribriform architecture. Therefore, complex 
glomeruloid pattern should not be classified as a variant of the more aggressive cribriform growth 
pattern in radical prostatectomy specimens. 
 Pathological grading of the glomeruloid growth pattern has been uncertain for a long 
time. At the 2005 ISUP conference, no consensus was reached on grading glomeruloid pattern 
due to lack of scientific evidence for its prognostic value.11 In 2009, Lotan and Epstein studied 45 
prostate cancer biopsies with glomeruloid features and found they were surrounded by Gleason 
pattern 4 structures in 80% and Gleason pattern 5 in 4% of cases.19 The authors noted that half of 
the glomeruloid structures were accompanied by cribriform pattern, which is in concordance with 
our findings. For this reason it was unanimously consented at the 2014 ISUP conference that 
glomeruloid glands should be assigned Gleason pattern 4, regardless of morphology.12  
Since the increased awareness of the dismal outcome of cribriform Gleason pattern 4, 
glomeruloid growth pattern has also been included in clinicopathological studies. Among 350 
radical prostatectomies with Gleason score 7 prostate cancer, Choy et al. found that patients with 
glomeruloid pattern had improved five-year biochemical recurrence-free survival in multivariable 
analysis, but had shorter survival than those with Gleason score 6.20 Glomeruloid growth pattern 
was associated with improved, although not statistically significant, metastasis-free survival of 
Gleason score 7 men in our previous radical prostatectomy study.16 However, both studies did not 
focus on glomeruloid architecture specifically and were performed on a Gleason score 7 cohort. 
The study of Kweldam et al. had a case-control study design and used metastasis-free survival as 
endpoint. We investigated glomeruloid architecture in a larger cohort of Grade Group 1 to 5 
prostate cancer and distinguished simple and complex glomerulations, which was not done in 




architecture was better than of those with cribriform architecture, and did not differ from those 
with poorly formed and fused glands only. Statistical analyses were hampered by the fact that 
glomeruloid architecture is rarely observed as single Gleason pattern 4, mostly coexisting with 
other growth patterns. 
Glomeruloid architecture is not a homogeneous Gleason pattern 4 subgroup. As 
previously reported by Lotan and Epstein, most glomerulations consisted of relatively small 
dilated glands, but some contain larger glomeruloid protrusions.19 Furthermore, a subset of 
glomerulations has fibrovascular cores. This is in line with three-dimensional renderings of 
glomeruloid structures which revealed an interconnecting network of tubules resembling Gleason 
pattern 3 glands with nodular epithelial proliferations near tubular branching points, or markedly 
curved tubules with small fibrovascular cores.96 While glomeruloid architecture is the most 
reproducible Gleason 4 growth pattern, interobserver variability exists for classifying glomeruloid 
structures with larger intraluminal cribriform protrusions.95 In this case, classification as either 
glomeruloid or cribriform architecture is uncertain, because the extent of cribriform intraluminal 
gland wall attachment has not been defined. Among Grade Group 2 prostate cancer patients, two-
thirds of specimens with complex glomeruloid pattern had concomitant cribriform pattern which 
might suggest that both patterns are related. Complex cribriform pattern for instance could be a 
tangential sectioning of cribriform architecture expanding into malignant tubules or might 
represent a precursor lesion. While designation of these structures as either cribriform or 
glomeruloid does not have clinical relevance if they coexist with cribriform architecture, their 
distinction might be important in diagnostic biopsies without cribriform structures. Active 
surveillance is mostly offered to men with biopsy Grade Group 1 disease, but some surveillance 
protocols are also including men with Grade Group 2 prostate cancer without cribriform 
architecture and/or low Gleason pattern 4 percentages.45, 61-64, 97 Therefore, classifying complex 
glomeruloid structures might directly affect clinical decision-making. Our current findings in 
radical prostatectomy specimens indicate that men with complex glomeruloid structures without 
concomitant cribriform growth have better outcome than those with cribriform architecture. 
Therefore, at this moment insufficient evidence exists for classifying complex glomeruloid pattern 
as cribriform Gleason pattern 4. 
The strong point of this study was the detailed histological review of a large cohort of 
radical prostatectomy specimens. In this study the distinction between glomeruloid and cribriform 
architecture was arbitrarily made by the extent of gland wall connection, which occupied at least 
half of the inner glandular surface in cribriform growth and less in the glomeruloid pattern. No 
standard definition of complex glomeruloid pattern has been formulated yet. Therefore, it is 
important that future studies define the morphological criteria for distinguishing complex 
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glomeruloid and cribriform growth patterns. Some pathologists might have interpreted the 
complex glomeruloid cases as cribriform, however our current results do not provide evidence for 
this classification. Finally, this study was limited by its retrospective design and relatively short 
follow-up of 57 months. 
In conclusion, glomeruloid architecture is observed in 34% of radical prostatectomy 
specimens. Patients with simple glomeruloid glands have similar clinicopathological 
characteristics and biochemical recurrence-free survival as poorly formed and fused glands in 
Grade Group 2 prostate cancer. Although complex glomeruloid glands are more often coexistent 
with cribriform growth pattern, biochemical recurrence and metastasis occurred significantly less 
frequently in this subgroup. Therefore, complex glomeruloid architecture does not classify as a 
cribriform Gleason 4 growth pattern in radical prostatectomy specimens. Further studies are 
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The Gleason score is an important parameter for clinical outcome in prostate cancer patients. 
Gleason score 8 is a heterogeneous disease including Gleason score 3+5, 4+4, and 5+3 tumours, 
and encompasses a broad range of tumour growth patterns. Our objective was to characterize 
individual growth patterns and identify prognostic parameters in Gleason score 8 prostate cancer 
patients.  
We reviewed 1,064 radical prostatectomy specimens, recorded individual Gleason 4 and 5 growth 
patterns as well as presence of intraductal carcinoma, and evaluated biochemical recurrence- and 
metastasis-free survival.  
Gleason score 8 disease was identified in 140 (13%) patients, of whom 76 (54%) had Gleason score 
3+5, 46 (33%) 4+4, and 18 (13%) 5+3 disease. Invasive cribriform and/or intraductal carcinoma 
(n=87, 62%) was observed more frequently in Gleason score 4+4 (93%) than 3+5 (47%; P<0.001) 
and 5+3 (44%; P<0.001) patients. Gleason pattern 5 was present in 110 (79%) men: as single cells 
and/or cords in 99 (90%) and solid fields in 32 (29%) cases. Solid field pattern 5 coexisted with 
cribriform architecture (23/32, 72%) more frequently than non-solid pattern 5 cases (36/78, 46%, 
P=0.02). In multivariable analysis including age, Prostate-Specific Antigen, pT-stage, surgical 
margin status and lymph node metastases, presence of cribriform architecture was an independent 
parameter for biochemical recurrence-free (Hazard Ratio (HR) 2.0, 95% Confidence Interval (CI) 
1.0-3.7; P=0.04) and metastasis-free (HR 3.5, 95% CI 1.0-12.3; P=0.05) survival. 
In conclusion, invasive cribriform and/or intraductal carcinoma occurs more frequently in 
Gleason score 4+4 prostate cancer patients than in Gleason score 3+5 and 5+3, and is an 
independent parameter for biochemical recurrence and metastasis. Therefore, cribriform 









The Gleason grading system for prostate cancer is based on classification of histomorphological 
growth patterns.8 At the 2014 meeting of the International Society of Urological Pathology (ISUP), 
consent was reached that a Grade Group should be reported in conjunction with the Gleason 
score, based on the initial work of Pierorazio et al., which was endorsed by the World Health 
Organization (WHO) in 2016.12, 38, 98. The Grade Group system is comprehensive and facilitates 
patient communication as it labels Gleason score 2-6 as Grade Group 1 and emphasizes the 
important distinction between Gleason score 3+4=7 (Grade Group 2) and 4+3=7 (Grade Group 
3) prostate cancer. Grade Group 4 prostate cancer encompasses Gleason score 8 tumours, 
including Gleason score 3+5, 5+3, and 4+4.58, 99 However, it is not yet clear whether these three 
Gleason score 8 subgroups have similar clinical outcome.  
The importance of distinguishing individual prostate cancer growth patterns is 
increasingly being acknowledged. Gleason pattern 4 encompasses four major growth patterns, 
including poorly formed, fused, glomeruloid and cribriform glands.12 The clinical relevance of 
cribriform architecture in prostate cancer has been well established in recent years, as it is 
associated with biochemical recurrence, metastasis and disease-specific death.13, 15, 16, 28, 34, 51, 91 
Intraductal carcinoma is characterized by a proliferation of malignant epithelial cells with 
cribriform or solid architecture distending pre-existent acini and prostatic ducts with preservation 
of basal cells.12 Although not incorporated in the Gleason score or Grade Group, intraductal 
carcinoma is independently associated with adverse oncological outcome.28, 35, 39 The adverse 
impact of invasive cribriform and intraductal carcinoma has mainly been studied in Gleason score 
3+4 prostate cancer, as it might affect clinical decision-making in this patient population in 
particular. Some studies indicate that presence of invasive cribriform and intraductal carcinoma 
also has independent predictive value in Gleason score 8 prostate cancer patients.39, 100  
While the impact of cribriform architecture is well recognized, little is known about the 
clinical relevance of individual Gleason 5 growth patterns.13 Gleason pattern 5 encompasses 
tumour growth in single cells, cords and solid fields.12 Furthermore, presence of comedonecrosis 
is considered Gleason pattern 5, whether it is present within papillary, cribriform or solid fields. 
Of notice, recent studies have shown that comedonecrosis more commonly occurs in intraductal 
carcinoma than in invasive carcinoma, requiring basal cell immunohistochemistry for their 
distinction.101-103 While Gleason score 8 prostate cancer is generally considered a high-risk disease 
requiring immediate therapeutic intervention, analysis of individual Gleason 4 and 5 growth 
patterns might attribute to risk stratification and optimize personalized treatment decisions. The 
objective of this study is to compare the clinical characteristics and outcome of Gleason score 3+5, 
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5+3, and 4+4 subgroups and to investigate the impact of invasive cribriform and/or intraductal 
carcinoma in Gleason score 8 radical prostatectomy specimens. 
 
 
Figure 6.1. Gleason pattern 4 and pattern 5 tumor morphology. A. Gleason pattern 4, small invasive 
cribriform structures, 15x. B. Gleason pattern 4, large invasive cribriform structures, 10x. C. Gleason pattern 
5, cords, 20x. D. Gleason pattern 5, small solid nests with subtle intervening stroma, 20x. E. Gleason pattern 






Materials and methods 
 
Patient selection 
Patients who had undergone radical prostatectomy for prostatic adenocarcinoma from three 
university medical centers in The Netherlands between 2000 and 2017 were included in this study; 
854 patients were operated at Erasmus MC, University Medical Center, Rotterdam; 96 at Leiden 
University Medical Center (LUMC), Leiden; and 137 at Antoni van Leeuwenhoek Hospital, the 
Netherlands Cancer Institute (NKI), Amsterdam. Whereas the radical prostatectomies from 
Erasmus MC were consecutive, those from LUMC and NKI were selected for presence of Gleason 
score 4+3 to 10 in the original pathology report. We excluded men who had undergone hormonal, 
radiation and/or viral therapy (n=23) prior to operation.40 Radical prostatectomy specimens were 
fixed in neutral-buffered formalin, after which they were sectioned transversely and embedded 
entirely for diagnostic purposes. All slides were available for pathology review. This study was 
approved by the institutional Medical Research Ethics Committee (MEC-2018-1614). 
 
Pathologic evaluation 
All 1,064 radical prostatectomy specimens were reviewed in common sessions by two investigators 
(EH, GvL), blinded to clinical outcome. For each specimen the following features were recorded: 
Gleason score and Grade Group according to the 2014 ISUP/2016 WHO guidelines, pT-stage 
according to the American Joint Committee on Cancer (AJCC) TNM 8th edition, surgical margin 
status, presence of intraductal carcinoma, and percent Gleason 4 and 5 growth patterns.12, 41 In 
case of multifocality we only monitored the characteristics of the index tumour defined as the 
tumour with the highest grade, stage or volume.  
The following Gleason 4 growth patterns were recognized: poorly formed, fused, 
glomeruloid and cribriform glands.12, 38 Furthermore, we distinguished small and large cribriform 
gland architecture (Figure 6.1, A-B), since the latter is associated with more aggressive behaviour.51 
Large cribriform structures were defined as having a diameter more than twice the size of adjacent 
benign glands. We examined the following Gleason 5 growth patterns: single cells, cords, and 
solid fields (Figure 6.1, C-F). Single cells and cords were grouped for analysis. Solid fields were 
divided into those with small solid nests containing 10 to 30 cells, and those consisting of medium 
to large solid fields with more than 30 cells. In case comedonecrosis was present in invasive 
cribriform or solid fields, this was considered Gleason pattern 5. Invasive cribriform Gleason 
pattern 4 and solid pattern 5 either with or without comedonecrosis were morphologically 
distinguished from intraductal carcinoma based on the following features: invasive cribriform and 
solid prostate cancer had irregular borders or formed interconnecting fields, well exceeding the 
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outline of distended pre-existent glands, or extended into periprostatic adipose tissue, ejaculatory 
ducts or seminal vesicles. Intraductal carcinoma was continuous with pre-existent glands lined by 
basal cells, or contained corpora amylacea. In case invasive cribriform or solid carcinoma and 
intraductal carcinoma could not be differentiated by morphological criteria alone, additional basal 
cell immunohistochemistry was performed. Basal cell immunohistochemistry (34BE12) was 
performed in 189/854 (22%) radical prostatectomy specimens from Erasmus MC, including 14/31 
(45%) Gleason score 8 tumours with cribriform or solid architecture; no paraffin blocks were 
available from the other hospitals. If basal cells were completely absent, the lesion was classified 
as either invasive cribriform Gleason pattern 4 or solid pattern 5 carcinoma. When sporadic, 
scattered or continuous basal cells were identified, the lesion was considered intraductal 
carcinoma. Intraductal carcinoma and tertiary patterns were not incorporated in the Gleason 
score.12, 31, 38 Minor high-grade components occupying <5% of the tumour volume were considered 
as tertiary pattern. The Grade Group concordance rate at revision was 88/135 (65%) for radical 
prostatectomies from NKI and 39/94 (41%) for specimens from LUMC. 
 
Clinical follow-up 
Clinical follow-up after radical prostatectomy consisted of six-monthly, and later annual 
monitoring of serum Prostate-Specific Antigen (PSA) levels. Biochemical recurrence was defined 
as PSA levels ≥ 0.2 ng/ml measured at two consecutive points in time, at least three months apart 
with undetectable PSA levels after operation, or as PSA increase of > 2.0 ng/ml when serum PSA 
had not declined to zero after operation. Post-operative lymph node and distant metastases were 
confirmed by biopsy or multidisciplinary consensus. 
 
Statistical analysis 
Continuous variables with normal distribution were analysed using the independent sample 
Student’s t-test for two groups, or One-way ANOVA for ≥3 groups. Variables without normal 
distribution were analysed using the Mann-Whitney U test for two groups, or Kruskal-Wallis test 
for ≥3 groups. For comparison of categorical parameters Pearson’s chi squared (χ2) test was used, 
and Fisher’s exact test in case of small numbers (n≤20). Missing PSA values (n=27) were imputed 
using the median PSA value. Biochemical recurrence-free survival and metastasis-free survival 
were analysed using Cox proportional hazards model and visualized by Kaplan-Meier curves. 
Statistics were performed using SPSS version 24 (IBM, Chicago, IL, USA). Results were 







Characteristics of Gleason score 8 prostate cancer patients 
Out of 1,064 radical prostatectomy specimens, 140 (13%) had Gleason score 8 prostate cancer. 
The median age of Gleason score 8 patients was 65.3 years (interquartile range (IQR) 61.4-68.5 
years) and median serum PSA level was 10.0 ng/ml (IQR 7.2-16.0 ng/ml). Gleason scores were 
distributed as follows: 76 (54%) men had Gleason score 3+5, 46 (33%) Gleason score 4+4, and 18 
(13%) Gleason score 5+3. Pathologic tumour stage was T2 in 67 (48%) men, T3a in 44 (31%) and 
T3b in 28 (20%). One (1%) patient had a T4 tumour and was grouped with T3b tumours for further 
analysis. Positive surgical margins were present in 68 (49%) cases. Pelvic lymph node dissection 
was performed in 91 (65%) men, 12 (9%) of whom had lymph node metastasis. Median follow-up 
time was 68.7 months (IQR 36.7-102.8).  
 
Clinicopathological features and outcome of Gleason score 3+5, 4+4 and 5+3 
The clinicopathological features of Gleason score 8 patients stratified for Gleason score are shown 
in Table 6.1. The median PSA level of patients with Gleason score 5+3 prostate cancer was 13.4 
ng/ml (IQR 8.8-26.8 ng/ml), significantly higher than for men with Gleason score 3+5 (10.0 
ng/ml; IQR 7.4-15.0 ng/ml; P=0.05) and Gleason score 4+4 (8.9 ng/ml; IQR 6.9-16.0 ng/ml; 
P=0.03). PSA levels of Gleason score 3+5 and 4+4 were comparable (P=0.45). Age, pT-stage, 
surgical margin status and lymph node metastases were not significantly different between groups. 
While Gleason pattern 4 constituted ≥95% of the tumour volume in Gleason score 4+4 by 
definition, it was present in 73/76 (96%) Gleason score 3+5 and 12/18 (67%) 5+3 tumours. The 
median percentage of Gleason pattern 4 was 30% (IQR 20%-35%) in 3+5 tumours and 18% (IQR 
0%-21%) in 5+3 tumours (P<0.001). Tertiary (<5%) Gleason pattern 5 was observed in 16/46 
(35%) Gleason score 4+4 tumours. 
Biochemical recurrence and post-operative distant metastasis were observed in 68 (49%) 
and 36 (26%) patients, respectively. Twenty-nine (63%) men with Gleason score 4+4 tumours 
experienced biochemical recurrence compared to 31 (41%, P=0.02) with Gleason score 3+5 and 
8 (44%, P=0.78) with 5+3. Biochemical recurrence-free survival was significantly shorter for 
patients with Gleason score 4+4 than Gleason score 3+5 (log rank P=0.02) prostate cancer. 
Gleason score 5+3 had the lowest absolute number of events and did not significantly differ from 
Gleason score 3+5 (log rank P=0.82) and Gleason score 4+4 (log rank P=0.26, Figure 6.2). A 
similar trend was found for post-operative metastasis. Metastases occurred in 18 (39%) men with 
Gleason score 4+4 compared to 14 (18%, P=0.01) with Gleason score 3+5 and 4 (22%, P=0.20) 














































































































































































































































































































































































































































































































































































































































































































































































































Figure 6.2. Kaplan-Meier curves of A. biochemical recurrence-free survival (log rank P=0.001), 
B. metastasis-free survival (log rank P<0.001) and C. disease-specific survival (log rank P=0.01) in 
Gleason score 8 patients stratified for Gleason score. 
 
 
Figure 6.3. Kaplan-Meier curves of A. biochemical recurrence-free survival (log rank P=0.001), 
B. metastasis-free survival (log rank P<0.001) and C. disease-specific survival (log rank P=0.01) in 
Gleason score 8 patients with invasive and/or intraductal cribriform carcinoma (CR/IDC+) and 




for patients with Gleason score 4+4 than Gleason score 3+5 (log rank P=0.006) prostate cancer. 
Gleason score 5+3 did not significantly differ from Gleason score 3+5 (log rank P=0.63) and 
Gleason score 4+4 (log rank P=0.25). The number of disease-specific deaths (n=12, 9%) was too 
low for subgroup analysis. 
 
Cribriform architecture in Gleason score 8 prostate cancer 
Invasive and/or intraductal cribriform carcinoma was present in 87 (62%) men, of whom 36 (41%) 
had Gleason score 3+5, 43 (49%) Gleason score 4+4, and 8 (10%) Gleason score 5+3 tumours. Of 
these, 83 (95%) had invasive and 48 (55%) had intraductal cribriform carcinoma. Both patterns 
were concurrently present in 44 (51%) men. Invasive cribriform carcinoma only was seen in 39 
(44%) men and intraductal cribriform carcinoma only in 4 (5%) men. Large cribriform carcinoma 
was present in 37 (43%) men with cribriform architecture and was always accompanied by small 
cribriform carcinoma. Invasive and/or intraductal cribriform carcinoma was observed more 
frequently in Gleason score 4+4 than in Gleason score 3+5 (93% versus 47%, P<0.001) and 5+3 
(93% versus 44%, P<0.001) tumours. Large invasive cribriform carcinoma also occurred more often 
in Gleason score 4+4 than in 3+5 (61% versus 8%, P<0.001) or 5+3 (61% versus 22%, P<0.001) 
tumours, while its appearance in Gleason score 3+5 and 5+3 was not significantly different 
(P=0.08) in this cohort. 
Gleason score 8 prostate cancer was stratified based on presence of invasive and/or 
intraductal cribriform carcinoma (Table 6.2). Non-organ confined disease  (63% versus 34%, 
≥pT3a, P=0.003) and positive pelvic lymph nodes (19% versus 3%, P=0.05) were more common 
in patients with cribriform architecture. Age, PSA levels and surgical margin status were not 
significantly different between Gleason score 8 patients with or without cribriform architecture. 
Patients with cribriform architecture had significantly shorter biochemical recurrence-free (log-
rank P=0.001), metastasis-free (log-rank P<0.001) and disease specific (log-rank P=0.01) survival 
than those without (Figure 6.3). 
 
Histomorphology of Gleason pattern 5 
Gleason pattern 5 was observed in 110 (79%) Gleason score 8 tumours. In addition to men with 
Gleason score 3+5 and 5+3, 16 (35%) men with Gleason score 4+4 had tertiary Gleason pattern 
5. Single cells and/or cords were present in 99/110 (90%) and solid fields in 32/110 (29%) 
tumours. All Gleason 5 patterns were simultaneously present in 26 (24%) cases. Invasive and/or 
intraductal cribriform carcinoma was present in 23/32 (72%) cases with solid pattern 5 and in 
36/78 (46%) cases with non-solid pattern 5 (P=0.02). Of interest, the nine solid field cases without 




Table 6.2. Gleason score 8 patients stratified for presence of cribriform architecture. 
 









63.7 (64.1; 59.7-67.4) 
 





12.5 (10.0; 7.0-14.0) 13.2 (10.0; 7.5-16.0) 0.33 
pT-stage 
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Gleason pattern 4 
   Small cribriform 














0 48 (55%) <0.001 
Gleason pattern 5 
   Single cells and/or cords 
   Small solid nests 
   Medium to large solid fields 

















Positive surgical margins  
 
25 (47%) 43 (49%) 0.80 
Pelvic lymph node dissection 










16 (30%) 52 (60%) 0.001 
Metastasis 
 
4 (8%) 32 (37%) <0.001 
Disease-specific death 
 
0 12 (14%) 0.004 
Values denote either mean (median; IQR) or n (%). PSA = Prostate Specific Antigen. 
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Comedonecrosis was present in 9 cases, 7 (78%) of which were present in Gleason score 4+4 
tumours. Comedonecrosis was accompanied by cribriform architecture in all 9/9 (100%) cases 
and by solid fields in 5/9 (56%) cases. Moreover, comedonecrosis was observed more often in 
patients with large cribriform fields (7/20, 35%) than in those without (2/90, 2%, P<0.001). 
 
Multivariable analysis of clinical outcome in Gleason score 8 patients 
In univariate Cox regression analysis, pT3a (Hazard Ratio (HR) 2.1, 95% Confidence Interval (CI) 
1.1-3.8, P=0.02), pT3b/4 (HR 4.6, 95% CI 2.5-8.5, P<0.001), Gleason score 4+4 (HR 1.9, 95% CI 
1.1-3.1, P=0.02), positive lymph nodes at time of operation (HR 11.8, 95% CI 5.6-25.2, P<0.001) 
and overall presence of invasive and/or intraductal cribriform carcinoma (HR 2.4, 95% CI 1.4-
4.1, P=0.003) were significantly associated with shorter biochemical recurrence-free survival, 
while age (P=0.18), PSA level (P=0.43), Gleason score 5+3 (P=0.78) and surgical margin status 
(P=0.21) were not (Table 6.3). In multivariable analysis, pT3b/4-stage (HR 4.4, 95% CI 2.1-9.3, 
P<0.001), positive lymph nodes (HR 9.9, 95% CI 4.2-23.5, P<0.001) and overall cribriform 
architecture (HR 2.0, 95% CI 1.0-3.7, P=0.04) had independent predictive value for biochemical 
recurrence-free survival, while Gleason score 4+4 (HR 1.7, 95% CI 1.0-2.9, P=0.07) did not meet 
conventional measures of significance in this cohort. In case individual cribriform growth patterns 
were included in multivariable analysis instead of overall cribriform architecture, large invasive 
cribriform carcinoma (HR 2.0, 95% CI 1.0-4.1, P=0.05) had independent predictive value for 
biochemical recurrence-free survival, whereas intraductal cribriform carcinoma (HR 1.3, 95% CI 
0.8-3.5, P=0.4) and small invasive cribriform carcinoma (HR1.6, 95% CI 0.8-3.5, P=0.2) did not 
(data not shown).  
Similar trends were observed for metastasis as pT3a (HR 2.7, 95% CI 1.2-6.2, P=0.02), 
Gleason score 4+4 (HR 3.8, 95% CI 1.8-8.1, P=0.001), positive lymph nodes (HR 11.5, 95% CI 
5.2-25.9, P<0.001) and overall cribriform architecture (HR 6.7, 95% CI 2.0-21.9, P=0.002) were 
significantly associated with shorter metastasis-free survival, whereas age (P=0.80), PSA level 
(P=0.96), pT3b/4 (P=0.06), Gleason score 5+3 (P=0.85) and positive surgical margins (P=0.95) 
were not (Table 6.4). In multivariable analysis, Gleason score 4+4 (HR 2.4, 95% CI 1.0-5.9, 
P=0.05), positive lymph nodes (HR 15.0, 95% CI 5.6-40.0, P<0.001) and overall cribriform 
architecture (HR 3.5, 95% CI 1.0-12.3, P=0.05) had independent predictive value for metastasis-
free survival. Due to the low number of events and risk of model overfitting we were not able to 






Table 6.3. Cox regression analysis for biochemical recurrence-free survival in Gleason score 8 
patients. 
 Univariate  Multivariable 
 HR* 95% CI P-value  HR 95% CI P-value 
Age (years) 1.0 0.9-1.0 0.18  1.0 0.9-1.0 0.05 
PSA (ng/ml) 1.0 1.0-1.0 0.43  1.0 1.0-1.0 0.23 
pT-stage        
   T2 ref    ref   
   T3a 2.1 1.1-3.8 0.02  1.8 1.0-3.4 0.06 
   T3b/T4 4.6 2.5-8.5 <0.001  4.4 2.1-9.3 <0.001 
Gleason score        
   3 + 5 ref    ref   
   4 + 4 1.9 1.1-3.1 0.02  1.7 1.0-2.9 0.07 
   5 + 3 1.1 0.5-2.4 0.78  1.5 0.6-3.6 0.37 
Positive surgical margins 1.4 0.8-2.2 0.21  0.8 0.5-1.5 0.55 
Pelvic lymph node metastasis 11.8 5.6-25.2 <0.001  9.9 4.2-23.5 <0.001 
Cribriform architecture 2.4 1.4-4.1 0.003  2.0 1.0-3.7 0.04 
*HR = hazard ratio, CI = confidence interval. 
  
91 
Table 6.4. Cox regression analysis for metastasis-free survival in Gleason score 8 patients. 
 
 Univariate  Multivariable 
 HR* 95% CI P-value  HR 95% CI P-value 
Age (years) 1.0 0.9-1.1 0.80  1.0 0.9-1.1 0.52 
PSA (ng/ml) 1.0 1.0-1.0 0.96  1.0 0.9-1.0 0.50 
pT-stage        
   T2 ref    ref   
   T3a 2.7 1.2-6.2 0.02  2.5 1.0-6.7 0.06 
   T3b/T4 2.4 1.0-6.0 0.06  1.3 0.4-3.8 0.67 
Gleason score        
   3 + 5 ref    ref   
   4 + 4 3.8 1.8-8.1 0.001  2.4 1.0-5.9 0.05 
   5 + 3 1.1 0.32-4.0 0.85  0.7 0.2-3.0 0.65 
Positive surgical margins 1.0 0.5-2.0 0.95  1.1 0.5-2.4 0.84 
Pelvic lymph node metastasis 11.5 5.2-25.9 <0.001  15.0 5.6-40.0 <0.001 
Cribriform architecture 6.7 2.0-21.9 0.002  3.5 1.0-12.3 0.05 







Our study demonstrates that among Gleason score 8 prostate cancer patients on radical 
prostatectomy, biochemical recurrence and metastases occur more often in Gleason score 4+4 
than in Gleason score 3+5 or 5+3 tumours. Invasive and/or intraductal cribriform carcinoma was 
observed in 62% of tumours and was associated with adverse pathological features and clinical 
outcome. Cribriform architecture occurred more frequently in men with Gleason score 4+4 (93%) 
than in those with Gleason score 3+5 (47%) and 5+3 (44%). In multivariable analysis, cribriform 
architecture was an independent parameter for biochemical recurrence- and metastasis-free 
survival, while Gleason score was not. Therefore, cribriform architecture also has important value 
for risk stratification among Gleason score 8 prostate cancer patients. 
Since the introduction of Grade Groups several reports have analysed the clinical 
outcome of Gleason score 3+5, 4+4 and 5+3 prostate cancer.98 Some of these studies found that 
men with Gleason score 3+5 at radical prostatectomy had reduced risk of biochemical recurrence 
among Gleason score 8 patients. 104, 105 Others did not find a difference among Gleason score 8 
subgroups or concluded that men with primary Gleason pattern 5 had worse outcome.100, 106-109 
This variability of results might be explained by the use of different specimen types and clinical 
outcome measures.110 Furthermore, Gleason score 8 is relatively uncommon, hampering statistical 
analysis on large numbers of patients or resulting in clustering of Gleason score 5+3 and 5+3 
tumours.109, 111 Finally, from a morphologically point of view, Gleason score 8 prostate cancer is a 
very heterogeneous disease including highly variable quantities of Gleason 3, 4 and 5 growth 
patterns. This heterogeneity might lead to significant interobserver variability in tumour grading. 
For instance, Shah et al. only found fair interobserver reproducibility for Gleason pattern 5 
assignment among 16 international expert genitourinary pathologists.112 Upon re-review of 40 
archival cases with Gleason score 5+3 prostate cancer, Kryvenko et al. assigned the same score in 
only 4 (10%) specimens, but upgraded 57.5% and downgraded 17.5% of cases.113 
Many studies demonstrated worse clinical outcome for patients with cribriform 
architecture.13, 15, 16, 28, 34 Most of these studies investigated cribriform architecture in intermediate 
grade prostate cancer, while the impact of cribriform architecture in Gleason score ≥4+3 is less 
well established. In Gleason score 7-10 prostate cancer biopsy patients, presence of cribriform 
architecture has been associated with advanced pathological stage and worse disease-specific 
survival compared to those with cribriform-negative biopsies.39, 59 Harding-Jackson et al. found 
cribriform architecture, but not Gleason score, to have independent predictive value for cancer-
specific survival in Gleason score 8 patients.100 In the current study, we confirmed that cribriform 
architecture had strong discriminative value, even in aggressive Gleason score 8 prostate cancer. 
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Both overall invasive cribriform and/or intraductal carcinoma as well as its more aggressive large 
cribriform variant were significantly more often observed in Gleason score 4+4, than 3+5 and 5+3 
disease. Since its association with adverse outcome, the high frequency of cribriform architecture 
might well explain the worse outcome of Gleason score 4+4 prostate cancer compared to those 
with 3+5 in our study, while the low number of 5+3 patients hampered powerful statistical 
analysis. Of interest, however, is that in multivariable analysis not only cribriform architecture but 
also Gleason score 4+4 had independent prognostic value for metastasis-free survival. A similar 
trend was observed for biochemical recurrence-free survival although the predictive value of 
Gleason score 4+4 did not reach conventional measures of significance (P=0.07). This implicates 
that other grading factors apart from cribriform architecture contribute to the worse outcome in 
Gleason score 4+4 patients. A possible explanation could be that Gleason score 4+4 disease has 
the lowest percent of Gleason 3 growth pattern, which is by definition present in less than 5% of 
the tumour volume. In 3+5 disease, percent Gleason pattern 3 theoretically varies from 50% to 
95%, while it occupies 5% to 50% in Gleason score 5+3 tumours. Some groups have shown 
independent prognostic value for percent Gleason pattern 4 and 5, which outperformed Gleason 
score.114 The inverse could well be true for percent Gleason pattern 3; if a tumour still has the 
biological capacity to mature into well-delineated glandular structures it is associated with better 
outcome.  
Little is known about the predictive value of individual Gleason grade 5 growth patterns, 
which have been reported as either single cells, cords, small solid cylinders, solid fields, and 
presence of  comedonecrosis.12 Single cells and/or cords are the most common Gleason pattern 
5.115, 116 Flood et al. found that presence of solid fields and number of different Gleason 5 growth 
patterns were associated with shorter biochemical recurrence-free survival in Gleason score 9-10 
prostatectomies.115 Compared to other Gleason 5 patterns, comedonecrosis was associated with 
non-organ confined disease and biochemical recurrence.103, 117 While individual Gleason 4 growth 
patterns have increasingly been subject to clinicopathological analysis, information on the clinical 
relevance of Gleason 5 patterns is still scarce. Our group recently performed in-depth three-
dimensional visualization of prostate adenocarcinoma architectural growth patterns and revealed 
two separate morphological groups.96 The first group consists of a tubular network in which the 
vast majority if not all tumour cells are in direct contact with surrounding stroma. This group 
encompasses the morphological continuum of Gleason pattern 3, poorly formed and fused pattern 
4, and single cells and cords pattern 5. The second group has contiguous epithelial proliferations 
in which the majority of tumour cells are not in contact with surrounding stroma and consists of 
cribriform pattern 4 and solid pattern 5 with or without comedonecrosis. Our current finding that 




current study, we distinguished between small nested cylinders consisting up to 30 tumour cells 
and larger solid fields. While the latter was continuous with cribriform growth, small nested 
cylinders were not. This suggests that both have different biological and possibly clinical relevance. 
However, larger studies are required to perform statistical analysis on the clinical relevance of 
individual Gleason 5 growth patterns. 
Strong points of this study are the detailed histological review of radical prostatectomy 
specimens and the classification of cribriform architecture with the use of strict morphological 
criteria and additional immunohistochemistry. The study is limited by the retrospective study 
design. The inclusion of high-grade samples from two participating centers could have resulted in 
a selection bias. Furthermore, the relatively short follow-up of 59 months and limited number of 
patients restricted robust statistical analysis. 
In conclusion, Gleason score 8 is a heterogeneous group of prostate cancers. Although 
clinicopathological characteristics of Gleason score 3+5, 4+4 and 5+3 are mostly similar, Gleason 
score 4+4 patients have a higher risk of adverse events. Cribriform architecture is an independent 
predictor for metastasis-free survival and has better discriminative value for clinicopathological 
outcome than Gleason score. Therefore, reporting cribriform architecture might add value in risk 

















Adapted from ‘Prostate cancer growth patterns beyond Gleason 
score: entering a new era of comprehensive tumour grading’ 
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Introduction 
Prostate cancer management depends on a multitude of parameters for optimal risk stratification. 
Prostate-Specific Antigen (PSA) level, clinical stage and histology of prostate biopsies are key 
components in predictive risk models and subsequent clinical decision-making. The Gleason 
grading system has important value for determining prostate cancer prognosis and clinical 
decision-making. The Gleason score is entirely based on classification of architectural growth 
patterns. These basic patterns are assigned a Gleason grade from 1 to 5. Since prostate cancer is 
such a heterogeneous disease, the Gleason score is determined by adding to the most common 
and highest grade in biopsies, or two most predominant grades in radical prostatectomy (RP) 
specimens.11, 118 Gleason pattern 1 to 3 encompass well-delineated glandular structures with 
variable inter-glandular distance and nodular circumscription. As no practical nor prognostic 
differences exist between these three Gleason grades, the International Society of Urological 
Pathology (ISUP) recommended that Gleason scores 2-4 should rarely, if ever, be used on biopsy 
specimens.11 Gleason pattern 4 includes poorly formed, fused, glomeruloid and cribriform 
glandular structures, whereas growth patterns with essentially no glandular differentiation such as 
single cells, cords, solid fields and presence of comedonecrosis classify as Gleason pattern 5 (Figure 
1).11, 12 While individual growth patterns have not been specified in pathology reporting, clinical 
decision-making or molecular-biological investigations, recent studies indicate that individual 
growth patterns have independent predictive value for clinical outcome and facilitate more 
comprehensive interpretation of molecular-biological findings. The aim of this Discussion is to 
summarize the clinicopathological impact of individual prostate cancer growth patterns beyond 
Gleason score and to investigate their molecular-biological background. Moreover, we aim to give 
recommendations on the incorporation of architectural growth patterns in order to optimize 
decision-making in clinical practice. 
 
Clinicopathological impact of cribriform growth patterns and their variants 
Individual tumour growth patterns have mainly been analysed in Gleason score 3+4=7 (Grade 
Group 2) prostate cancer, which is composed of variable quantities of well-delineated Gleason 
pattern 3 glands and Gleason pattern 4 structures. In 2011, Iczkowski et al. were the first to report 
that cribriform growth pattern had independent prognostic value for post-operative PSA failure.13 
Many groups have thereafter confirmed the independent predictive value of cribriform pattern for 
adverse pathological features, biochemical recurrence- and disease specific-free survival in biopsy 
and RP specimens.14, 15, 20, 21, 34, 39, 52, 67, 71, 119, 120 However, a caveat of many studies on cribriform 
growth pattern is that it is not entirely clear whether, and if so how, invasive Gleason pattern 4 




by a cribriform or solid proliferation of atypical epithelial cells within distended pre-existent 
prostate acini either with or without comedonecrosis, and has also been associated with adverse 
clinical outcome.28, 36, 39, 52, 121-123 The aetiology of IDC is not yet elucidated. While IDC is thought 
to represent cancerisation of pre-existent glands by an invasive carcinoma, some data suggests that 
IDC arises as a precursor lesion that has progressed beyond high grade prostatic intraepithelial 
neoplasia (hgPIN).25 Invasive cribriform carcinoma and IDC are often difficult, if not impossible, 
to distinguish without the application of basal cell immunohistochemistry. If no basal cells are 
present, a cribriform lesion is generally considered as invasive Gleason pattern 4; if continuous, 
scattered or sporadic basal cells are observed, cribriform architecture is mostly regarded as IDC. 
Only few studies have attempted to investigate invasive cribriform and intraductal carcinoma 
separately by using extensive immunohistochemistry.34, 39, 51 In a prostate biopsy screening cohort 
of 1,031 men, Kweldam et al. found that presence of invasive cribriform carcinoma and IDC were 
both associated with worse disease-specific survival in univariate analyses. The combination of 
either invasive cribriform or intraductal carcinoma showed the strongest association with outcome 
in this study. In the vast majority of patients, IDC occurs intermixed with invasive carcinoma, but 
rare cases of isolated IDC without invasive disease have been described.24  
Grading of IDC intermixed with invasive carcinoma has been controversial. While the 
2014 ISUP meeting did not make a recommendation on this issue, the 2016 WHO states it should 
not be factored into grading.12, 118 A consequence of the WHO recommendation is that basal cell 
immunohistochemistry should be performed in every case where IDC cannot be distinguished 
from invasive disease and classification of atypical lesion as either IDC or invasive carcinoma 
would alter the final Gleason score. Apart from additional run-around time and costs, basal cell 
immunohistochemistry does not distinguish between invasive cribriform or solid carcinoma, and 
IDC in every case. It is well-known that foci of hgPIN can lack basal cells probably due to sampling 
artifact. As IDC glands are by definition distended, the chance of false-negative basal cell 
immunohistochemistry seems even larger, resulting in erroneous classification as invasive 
cribriform pattern. On the other hand, large irregular cribriform tumour fields well exceeding pre-
existent gland architecture might have rare basal cells, as has also rarely been reported for low-
grade invasive adenocarcinoma.124 Since IDC is an adverse pathological parameter and difficult 
or even impossible to distinguish from invasive carcinoma, even with the use of basal cell 
immunohistochemistry, it is recommended by the latest 2019 ISUP consensus meeting that IDC 
intermixed with invasive carcinoma should be assigned a Gleason grade based on its underlying 
growth pattern, as if it were invasive carcinoma.125 This incorporation of intraductal carcinoma 
into the tumour grade results in a Grade Group change in less than 2% of prostate cancer 
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biopsies.126 Although the modification might affect decision-making in individual patients, it has 
minimal impact on overall prostate cancer management. 
With increasing awareness of the their clinical impact, proposals for subclassification of 
cribriform growth patterns have been made. More detailed analysis of cribriform pattern has 
shown that the number of cribriform fields does not seem to affect clinical outcome in a negative 
way, while their maximal individual size does.34, 39, 51 In the current thesis, , we found in 420 Grade 
Group 2 RPs that large expansile cribriform fields, arbitrarily defined as exceeding at least two 
times the size of adjacent benign glandular structures, had seminal vesicle invasion in 32% and 
pelvic node metastasis in 23% of cases, which was significantly higher than 9% and 5% found, 
respectively, for small invasive cribriform carcinoma.51 Other groups have also separated both 
cribriform patterns, but are difficult to compare as they applied other size criteria such as presence 
of at least 12 intercellular lumens or exceeding average benign gland diameter.13, 34, 127 Therefore, 
we concluded that large cribriform carcinoma was an even more aggressive subtype. 
 
Clinical implications of incorporating cribriform growth patterns 
Since they both have independent predictive value, the presence of either invasive cribriform or 
intraductal cribriform carcinoma should routinely be reported as “cribriform carcinoma”.125 The 
question arises as to what extent incorporation of cribriform carcinoma can lead to optimization 
of therapeutic decision-making in individual prostate cancer patients. Patients with biopsy 
Gleason score 3+4=7 (Grade Group 2) prostate cancer will generally be offered definitive 
treatment, while those with Gleason score 3+3=6 (Grade Group 1) are often eligible for active 
surveillance. Recent identification of additional prognostic pathological parameters such as 
presence of invasive and/or intraductal cribriform carcinoma and Gleason pattern 4 quantity, 
allows for more detailed risk stratification of men with Grade Group 2 disease. Men with low 
biopsy Gleason pattern 4 quantity might be eligible for active surveillance, firstly because their 
outcome is comparable to those with Grade group 1 tumours, secondly due to the substantial inter-
observer variability for grade assignment to small foci of poorly formed and fused glands.43, 44, 128-
131 Since disease-specific and biochemical recurrence-free survival are not statistically significantly 
different among men with biopsy Grade Group 2 without cribriform carcinoma and those with 
Grade Group 1, absence of both invasive cribriform and intraductal carcinoma has also been 
proposed as an eligible criterion for active surveillance for men with Grade Group 2 biopsies.39, 48, 
52, 132 If the safety of this eligibility approach is shown in prospective studies, this will have major 
impact on individual Grade Group 2 patient management. Presence of invasive carcinoma might 
also affect other aspects of clinical decision-making. Absence of cribriform architecture has been 




22/228 (10%) Grade Group 2 men with cribriform carcinoma developed metastases, while no 
metastases were observed among 192 cribriform-negative Grade Group 2 and 207 Grade Group 1 
patients (this thesis).133 Although higher biochemical recurrence rates were seen in men with Grade 
Group 2 prostate cancer, this did not affect long term outcome in our cohort. This indicates that 
invasive cribriform and intraductal carcinoma, in particular, might have an impact on the 
biological potential for metastatic disease to develop. In contrast, postoperative biochemical 
recurrence-free survival is also related to tumour volume parameters and surgical technique, which 
do not necessarily reflect biological derangement caused by the disease. 
Current guidelines on performing of pelvic lymph node dissections (PLND) are based on 
clinicopathological nomograms which do not consider cribriform architecture, but future inclusion 
of invasive cribriform and intraductal carcinoma might result in optimization of these nomograms. 
Few studies also have found independent value of cribriform carcinoma for response to radiation 
therapy and docetaxel, but the definitive clinical impact on these treatment modalities remains to 
be determined.121, 134, 135 
 
Detection of cribriform growth patterns with MRI and prostate biopsies 
Since invasive cribriform and intraductal carcinoma might increasingly affect clinical decision-
making, the sensitivity for detection of these adverse features on biopsy should ideally be high. 
Concordance between Grade Group at RP specimens and matched biopsies is relatively low, with 
tumour up-grading occurring in up to 40% of cases.94, 136 The sensitivity and specificity for 
identification of invasive and/or intraductal cribriform carcinoma at biopsy specimens varies from 
43-56% and 87-95%, respectively.59, 137, 138 This indicates that about half of cribriform carcinoma 
lesions are missed at diagnostic biopsies. Detailed analysis of features potentially associated with 
cribriform false-negative biopsies, did not reveal predictive value for number of positive biopsies, 
percent Gleason pattern 4, or presence of glomeruloid Gleason pattern 4 architecture in a relatively 
small series performed in this thesis.138 On the other hand, multiparametric magnetic resonance 
imaging (MRI) might have added value in identification of men with prostatic invasive cribriform 
and intraductal carcinoma with false-negative biopsies, since these more frequently present with 
PI-RADS score 5 lesions.49, 138, 139 Finally, commercially available molecular tests might also play 







Invasive cribriform growth pattern delineation 
As invasive cribriform carcinoma should be separately commented on in pathology reports and 
might increasingly affect individual therapeutic decision-making, it is important to gain broad 
consensus on the definition of cribriform morphology and to delineate this growth pattern from its 
microscopic mimickers.65 Recognition and Gleason pattern 4 assignment is better for cribriform 
and glomeruloid growth pattern than for poorly-formed and fused glands.94, 95, 131 Nevertheless, 
tangentially sectioned tumour glands, complex fused glands, large glomeruloid structures and 
solid Gleason pattern 5 might all be confused with invasive cribriform pattern.95 Our group has 
defined cribriform architecture as an epithelial sheet (a) where the majority of tumour cells do not 
contact surrounding stroma, (b) with a polarized gland-like structure being present at less than half 
of the sheet circumference and (c) with regular intercellular lumens clearly visible on HE section 
(Figure 2).65, 143 The first criterion (a) distinguishes cribriform from complex fused glands where 
most if not all tumour cells are still in direct contact with subtle connective tissue cores being 
present within the lesion. The second criterion (b) arbitrarily distinguishes cribriform from large 
glomeruloid pattern where polarized gland-like spaces are circumventing more than half of the 
central protrusion. The validity of this criterion is supported by the fact that clinicopathological 
features and biochemical recurrence-free survival of large glomeruloid structures at RP were more 
comparable to those of small glomeruloid than cribriform Gleason pattern 4 in our study (this 
thesis).144 The third criterion (c) distinguishes cribriform from solid Gleason pattern 5 where 
essentially no glandular differentiation is visible on HE sections.  
 
Clinicopathological relevance of other  growth patterns 
Whereas invasive cribriform and intraductal carcinoma have independent value for clinical  
outcome in men with Grade Group 2 prostate cancer, it is not entirely clear yet to what extent 
outcome of Grade Group 2 men without cribriform architecture differs from those with Grade 
group 1 tumours. With a median follow-up of 13 years, Kweldam et al. did not find statistically 
different disease-specific survival for 256 patients with biopsy cribriform-negative Grade group 2 
and 486 Grade group 1 prostate cancer.52 In our RP cohort, we did not find any metastasis at 
PLND or during follow-up in207 men with Grade Group 1 and 197 Grade Group 2 cancer without 
invasive cribriform or intraductal carcinoma.133 The latter group, however, had significantly 
shorter biochemical recurrence-free survival than men with Grade Group 1. These data suggest 
that cribriform architecture is reflective of intrinsic capacity for development of metastasis, while 
the risk of biochemical recurrence also more depends on other factors such as tumour volume, 
positive surgical margins on non-cribriform Gleason patterns. In a detailed study of 1275 RPs, 




outcome of cribriform architecture compared to poorly-formed glands, they revealed reactive 
stroma response to be associated with worse and mucin extravasation with better prognosis.  
Hitherto, the glomeruloid growth pattern has not yet been adequately addressed in 
literature. In 1995, glomerulations were described for the first time in prostate needle biopsies.145 
Glomeruloid growth consists of carcinoma glands with intraluminal cell clusters or cribriform 
structures, attached to one side of the gland wall, resembling a glomerulus.12 Pacelli et al. were the 
first to describe the glomeruloid growth pattern in relation to higher tumour grade and pathological 
stage.92 Lotan et al. observed the glomeruloid growth pattern often simultaneously with high 
tumour grade and especially cribriform growth.19 Because of its morphological reminiscence and 
frequent co-occurrence with cribriform pattern, glomeruloid architecture has been classified as 
Gleason pattern 4 since the 2014 ISUP consensus meeting, and some authors have postulated it 
to represent a precursor of cribriform morphology.12, 19, 20 In 350 RP specimens with Gleason score 
7, Choy et al. however found that cribriform morphology independently increased the risk of 
biochemical recurrence, while glomeruloid architecture was significantly associated with a 
reduced risk.20 The previously mentioned study by McKenney et al. could not associate 
glomerulations with adverse recurrence-free survival.21 In our study among 472 Grade group 2 
RPs, we distinguished small simple glomerulations and complex glomerulations with cribriform 
protrusions (this thesis).144 Complex glomerulations coincided with cribriform architecture more 
often than simple glomerulations. Men with cribriform morphology had significantly worse 
clinicopathological features and biochemical recurrence-free survival than those with glomeruloid 
pattern, irrespective of the size of the glomerulations.  These findings seem counterintuitive with 
the hypothesis that glomeruloid glands are precursors of cribriform architecture. 
 Still little is known on the clinical relevance of Gleason 5 growth patterns, which have 
been classified as single cells, cords, solid fields, or presence of comedonecrosis.118 This is mostly 
due to the fact that tumours with primary, secondary or tertiary Gleason pattern 5 are very 
heterogeneous with variable quantities of Gleason pattern 3 , 4 and 5, several different growth 
patterns and occurrence of IDC. Meaningful statistical analysis including all relevant covariates 
requires inclusion of a large number of these patients. In that sense, it is of interest that even in 
Grade Group 4 patients, presence of cribriform architecture has independent predictive value for 
biochemical recurrence-free and disease-specific survival.39, 100, 146 In our cohort, presence of 
cribriform architecture outperformed Gleason score in predicting outcome regarding biochemical 
recurrence- and metastasis-free survival (this thesis).146 Nevertheless, presence of comedonecrosis 
and solid sheets were found to be adverse parameters amongst Gleason 5 patterns in two relatively 
small series.115, 117 
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Molecular aberrations in cribriform architecture 
Genomic features of prostate cancer differ from other cancers, firstly due to the relatively low 
mutation rate in prostate cancer. It features copy number variations involving prostate oncogenes 
and tumour suppressor genes, and continuous, accumulating genomic and epigenetic 
alterations.147, 148 The TMPRSS2-ERG fusion is one of the most common alterations, seen in 50% 
of prostate cancers, and is associated with low-grade tumours.149 The androgen receptor pathway 
is a key element in prostate cancer progression and harbours alterations in most castration-resistant 
prostate cancers.150 In addition, gains of oncogene c-MYC, loss of tumour suppressor gene PTEN 
and mutations in the SPOP gene have been associated with aggressive disease.151-155 
Molecular alterations in prostate cancer have mostly been examined by Gleason score 
without taking underlying growth patterns into account. Recently, few groups have aimed to 
identify molecular characteristics of invasive cribriform and intraductal carcinoma.18, 78, 79 Since 
these bioinformatic analysis were  performed retrospectively on publically available databases with 
digitally scanned HE reference slides, no reliable distinction between invasive and intraductal 
cribriform carcinoma could be made. Cribriform carcinoma is characterised by genomic instability 
and has been posited to be the result of an accumulation of aggressive features above early phase 
tumour alterations within the prostate epithelium.18, 78 Amongst others, deletions of 8p, 10q and 
amplification of 8q24 corresponding to PTEN loss and c-MYC gain were significantly enriched in 
cribriform carcinoma, together with SPOP point-mutations.18, 78, 79, 156, 157 Molecular profiling and 
RNA in situ hybridization revealed that the long noncoding RNA SChLAP1 had more than 3-
fold higher levels in cribriform architecture, and could serve as a potential marker for its detection 
in clinical practice.78, 158 Epigenetic alternations have been detected in cribriform prostate cancer 
as well. The hypermethylated clusters found in prostate cancer are enriched by cribriform patterns, 
while non-cribriform patterns dominate the hypomethylated cluster.79, 159, 160 Interestingly, various 
of the molecular aberrations associated with cribriform carcinoma have been linked to aggressive 
clinical behaviour of prostate cancer before.161-166 Moreover, distant metastasis were found to be 
partially comparable to intraductal cribriform carcinoma.80 Together these data indicate that 
cribriform carcinoma is a morphological substrate of increased genomic instability, and brings 
histopathology, molecular aberrations and adverse clinical outcome comprehensively together. 
 Molecular identification of a “cribriform signature” is of importance, especially since the 
high rate of false cribriform-negative biopsies is a limitation for developing clinical decision models 
incorporating cribriform carcinoma. A clinically applicable molecular urine, serum or tissue test 
might identify men at risk for unsampled cribriform carcinoma. Recently, studies have shown that 
higher risk scores using RNA expression-based tissue arrays (Decipher, Oncotype Dx and Prolaris) 




analysed.140, 141, 167 It remains to be determined whether these molecular assays still have added 
clinical value if cribriform carcinoma and percent Gleason pattern 4 are accounted for, and if they 
can support identification of men with false cribriform-negative prostate cancer biopsies. 
 
Three-dimensional architecture of prostate cancer growth patterns 
Microscopic diagnostic pathology in everyday practice is performed using thin tissue slides 
representing two-dimensional cross-sections of a three-dimensional (3D) structure. Little is known 
on the actual 3D architecture of prostate carcinoma growth patterns. Registration of hundreds of 
consecutive slides have shown that poorly-formed Gleason pattern 4 is continuous with Gleason 
pattern 3.168, 169 Recent improvements in tissue clearing techniques, long-distance confocal laser 
scanning and light-sheet microscopy have enabled imaging of intact 1 mm thick prostate tissues.170-
172 By detailed 3D analysis of formalin-fixed paraffin-embedded RP specimens, we were able to 
get comprehensive insight of the 3D architecture of prostate adenocarcinoma growth patterns.143 
This revealed that Gleason pattern 3 three-dimensionally represented tubules with local 
interconnections. This pattern was continuous with both poorly formed Gleason pattern 4 where 
tubular size and lumen diameter was smaller and tubular interconnections occurred more 
frequently, and fused pattern 4 where interconnections often occurred at distances smaller than 
the tubular diameter. In fact, single cells and cords Gleason pattern 5 formed a continuum with 
poorly formed glands, in which lumen size further decreased until its disappearance. On the other 
hand cribriform Gleason pattern 4 and solid pattern 5 either without or with comedonecrosis 
consisted of serpentine fields of epithelial cells with the majority of tumour cells not being in direct 
contact with surrounding stroma. Both patterns formed a continuum with or without the presence 
of recognizable intercellular lumens. Based on these three-dimensional features, we classified the 
growth patterns in two distinct subgroups which both formed continua. The first group consisted 
of Gleason pattern 3 tubules, Gleason pattern 4 poorly formed and fused glands, and Gleason 
pattern 5 single cells and cords, which all consisted of cells directly contacting surrounding stroma, 
but with variable gland size, lumen size and number of interconnections. The second group 
encompassed cribriform Gleason pattern 4 and solid pattern 5 without or with comedonecrosis 
consisting of epithelial cells, where the majority of cells did not connect to adjacent stroma and 
with variable intercellular lumen frequency and size. Glomeruloid structures formed a 3D 
intermediate between both subgroups. They represented intraluminal protrusions of epithelial cells 
appearing within a background of Gleason pattern 3 tubules and were mostly present at the side 
of tubular interconnections. The 3D architectural continuity and  transitions between growth 
patterns in both subgroups well explains Gleason grading inter-observer variability.94, 136 Whereas 
growth patterns are ordinally classified in Gleason grades in clinical practice, they gradually 
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transition to each other without presence of clearly identifiable cut-offs. Furthermore, the 3D 
architectural relationships support the definition and delineating characteristics of cribriform 
growth pattern as mentioned previously. Future studies need to determine whether the 3D 
dichotomization is also reflected by clinical and molecular observations.  
 
Digital image analysis for automated detection of cribriform growth pattern 
Digitalization in the field of pathology offers advantages in cancer diagnosis with the use of deep 
learning algorithms.173-175 In radiology, computer-aided detection of prostate cancer in 
multiparametric MRI images has similar performance scores as a radiologist, including to 
differentiate between low- and high-grade prostate cancer.176, 177 For histological evaluation, deep 
learning systems can be designed to segment epithelial tissue and recognize malignant glands. In 
prostate needle biopsies, cancer likelihood maps have been computed with high sensitivity for 
carcinoma.178 Hence, up to a third of slides not containing prostate cancer could be identified 
reliably and would not have to be evaluated by pathologists. Based on unforcedly generated 
features, deep learning systems are able to compute boundaries and cut-off points, thus enabling 
automated identification of histomorphological growth patterns.178-180 As mentioned before, 
prostate cancer grading is prone to intra- and interobserver variability, while treatment options and 
outcome are highly dependent on assignment of patterns. By standardization, image analysis is 
able to reduce the variability and prioritize cases for the pathologist. In a collaborative study we 
focused on automated detection of cribriform growth in prostate cancer based on convolutional 
neural networks.181 Original annotations performed by pathologists in prostate cancer biopsies 
showed that sensitive cribriform region detection can be reached, but at the expense of a high 
number of false positives.  
 
Future perspectives 
Last decade the growing interest in individual growth patterns in prostate cancer has resulted in 
identification of cribriform architecture as pathological factor with independent prognostic value.65 
However, the morphogenetic background of cribriform and other growth patterns remains to be 
elucidated. Furthermore, the relation of intraductal carcinoma and invasive cribriform carcinoma 
with show significant morphological overlap is yet unclear. To solve this issue, detailed molecular 
analyses of individually dissected growth patterns is mandatory. Furthermore cell culture and 
xenograft studies are subsequently important for investigating morphogenetic effects of specific 
molecular alterations. 
In turn, molecular markers might contribute to detection and diagnosis of cribriform 




detect cribriform architecture is unsatisfactory, although the false negative rate is lower for the 
large cribriform subtype. In future studies it should be determined how  multiparametric MRI and 
possibly commercially available molecular urine- or tissue-based tests could optimize the 
representability of prostate biopsies for the entire tumour.  
Future multivariable analyses need to elucidate on the mutual interaction and 
independent value of the recently explored pathological parameters such as cribriform patterns 
and percentage Gleason pattern 4 and 5. After identification of the independent, most influential 
and reproducible factors, modification to the current Gleason grading/Grade group systems could 
even be made to increase the discriminative value of tumour grading.53, 65 Furthermore, prospective 
studies including cribriform architecture in clinical decision-making for instance on eligibility for 




Presence of cribriform architecture is associated with dismal outcome with large cribriform 
architecture representing an even more aggressive subtype in prostate cancer. While 
glomerulations may harbour cribriform intraluminal protrusions, they had favourable outcome 
and should not be classified as a cribriform growth pattern variant. Treatment of patients with 
cribriform architecture is essential, but the sensitivity of cribriform growth pattern detection at 
biopsies should be improved. Incorporation of cribriform growth patterns beyond heterogeneous 
Gleason groups in pathology reporting and clinical decision-making will improve personalized 
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Prostate cancer is the most common cancer among men with great variability regarding outcome. 
Clinical decision-making depends on Prostate-Specific Antigen (PSA) levels, clinical tumour stage 
and Gleason score. The Gleason score is the most important parameter given by the clinical 
pathologist and is entirely based on tumour architectural growth patterns, which are classified into 
five different grades. The tumour is assigned a primary grade followed by a highest grade in needle 
biopsy or secondary grade in radical prostatectomy specimens. Men with Gleason score 3+3=6 
(Grade Group 1) prostate cancer have excellent outcome and are frequently eligible for active 
surveillance. Men with Gleason score 3+4=7 (Grade Group 2) or higher generally receive 
radiation therapy or radical prostatectomy surgery. Despite the urge for active treatment, 
differences in clinical outcome are observed in intermediate to high risk prostate cancer patients. 
There is a need for additional parameters to aid risk stratification in these men. Incorporation of 
individual histopathological growth patterns might be able to support optimal decision-making in 
this large prostate cancer subpopulation. 
Last decade the cribriform growth pattern has been recognized as independent prognostic 
pathological feature for prostate cancer outcome. Cribriform architecture however does not 
comprise one entity. Chapter 2 elaborated on the prognostic impact of invasive and intraductal 
cribriform prostate cancer subtypes in Grade Group 2 radical prostatectomies. Cribriform 
architecture was associated with worse clinicopathological parameters such as tumour stage and 
lymph node metastasis. Of the 420 radical prostatectomies, 8% revealed invasive large cribriform 
architecture, based on a diameter of at least twice the size of adjacent pre-existent normal glands. 
Large cribriform architecture represented an aggressive subtype of invasive cribriform prostate 
cancer as it was an independent predictive factor for biochemical recurrence-free survival in 
patients with Grade Group 2 prostate cancer. Furthermore, metastases were more often seen in 
this cribriform subtype. If validated in biopsy cohorts, large cribriform pattern therefore could serve 
as a new predictive parameter for optimisation of clinical decision-making. 
In order to incorporate cribriform architecture as predictive parameter, it is essential to detect it in 
diagnostic biopsies. In Chapter 3, we compared presence of cribriform architecture in biopsies and 
following radical prostatectomies. Patients had cribriform architecture on radical prostatectomy 
in 69% of cases, while on biopsies only 30% revealed this pattern. Of patients with Grade Group 
2 prostate cancer, 40% had false negative biopsies for cribriform growth. These patients presented 
with higher PSA levels than men with true negative biopsies for cribriform growth and more often 
had radiological high grade lesions on magnetic resonance imaging. The false negative rate for 




cribriform architecture. Also, biochemical recurrence-free was significantly worse for patients with 
true positive biopsies than false negative biopsies.  
It has been well established that cribriform architecture is associated with dismal outcome, 
however absence of this pattern was less well studied. Chapter 4 compared features and outcome 
of Grade Group 1 and Grade Group 2 prostate cancer without cribriform architecture. Although 
patients with cribriform-negative Grade Group 2 prostate cancer presented with higher PSA levels 
and higher frequency of extra-prostatic extension and positive surgical margins, this did not affect 
long-term outcome. Metastasis and disease-specific death occurred neither in patients with Grade 
Group 1 nor in cribriform-negative Grade Group 2. Biochemical recurrence-free survival was 
shortened in cribriform-negative Grade Group 2 patients, however this is also related to tumour 
volume parameters and surgical technique, which do not necessarily reflect biological 
derangement caused by the disease. 
Glomeruloid growth is a hitherto poorly understood histomorphological pattern that bears 
similarities to cribriform architecture. Glomerulations with small intraluminal protrusions have 
been associated with favourable outcome. It is yet unclear what is the clinical behaviour of 
complex glomeruloid patterns, which resemble cribriform architecture. In Chapter 5 we 
specifically aimed at characterization of glomeruloid architecture in radical prostatectomy 
specimens. Complex glomeruloid often coincided with other cribriform patterns. Although 
complex glomerulations were associated with slightly worse clinicopathological features, no 
independent prognostic value was seen for neither simple nor complex cribriform growth. 
Therefore, glomeruloid pattern and particularly complex glomerulations should not be classified 
as a cribriform growth pattern variant. 
Chapter 6 focused on the effect of growth patterns in Grade Group 4 prostate cancer. Although 
the incorporation of growth patterns in prostate cancer diagnosis particularly affects clinical 
decision making in Grade Group 2 prostate cancer, it might also have predictive value in high-
grade prostate cancer. We investigated presence of cribriform architecture in Grade Group 4 and 
found that it was present in 62% of cases. It was more frequently present in Gleason score 4 + 4 
compared to 3 + 5 or 5 + 3 prostate cancer, and solid field pattern 5 often coexisted with cribriform 
architecture. Presence of cribriform architecture was an independent parameter for biochemical 
recurrence- and metastasis-free survival. Therefore, cribriform architecture also has added value 
in risk stratification of Gleason score 8 prostate cancer patients. 
Finally, in Chapter 7 the main findings of this thesis are summarized and reviewed together with 
current available knowledge on prostate cancer growth patterns. We also postulate how 
incorporation of cribriform architecture can optimize personalized clinical decision-making in 




Prostaatkanker is de meest voorkomende kanker onder mannen, met grote variabiliteit in 
uitkomst. Klinische besluitvorming is afhankelijk van Prostaat-Specifieke Antigeen (PSA) levels, 
klinisch tumorstadium en Gleason score. De Gleason score is de belangrijkste door de klinisch 
patholoog afgegeven parameter en is gebaseerd op groeipatronen binnen de tumor, welke worden 
ingedeeld in vijf graden. Aan iedere tumor wordt een primaire graad toegekend, gevolgd door een 
hoogste graad in prostaatbiopten en secundaire graad in radicale prostatectomieën. Mannen met 
Gleason score 3+3 (Grade Group 1) prostaatkanker tonen excellente overleving en komen meestal 
in aanmerking voor actief vervolgen. Mannen met Gleason score 3+4 (Grade Group 2) of hoger 
ontvangen meestal behandeling in de vorm van radiotherapie of chirurgie. Ondanks de indicatie 
voor behandeling zijn er grote verschillen in klinische uitkomst tussen prostaatkanker patiënten 
uit deze intermediair tot hoog risico groep. Incorporatie van individuele histopathologische 
groeipatronen kan een additionele parameter in risicostratificatie zijn en optimale klinische 
besluitvorming faciliteren in deze grote prostaatkanker subpopulatie. 
In het afgelopen decennium is cribriforme groeiwijze geïdentificeerd als onafhankelijke 
prognostische parameter bij prostaatkanker. Cribriforme architectuur omvat echter niet slechts één 
entiteit. Hoofdstuk 2 onderzocht de prognostische waarde van subtypes van invasieve en 
intraductale cribriforme prostaatkanker in radicale prostatectomieën met Grade Group 2. 
Cribriforme architectuur was geassocieerd met ongunstige clinicopathologische parameters zoals 
hoog tumorstadium en lymfekliermetastasen. Van de 420 radicale prostatectomieën toonde 8% 
groot cribriforme groei, gebaseerd op een diameter van ten minste tweemaal die van een pre-
existente buis. Groot cribriforme groei representeerde een agressief subtype cribriforme 
architectuur, daar het een onafhankelijke predictieve waarde had aangaande biochemisch recidief-
vrije overleving in patiënten met Grade Group 2 prostaatkanker. Metastasen werden eveneens 
vaker gezien in dit cribriforme subtype. Wanneer deze parameter gevalideerd zou worden in een 
groot cohort, kan groot cribriforme groei een nieuwe predictieve parameter worden ter 
optimalisatie van klinische besluitvorming. 
Om cribriforme architectuur en subtypes te incorporeren als predictieve marker, is het essentieel 
deze in diagnostische biopten op te sporen. In hoofdstuk 3 vergeleken we de aanwezigheid van 
cribriforme architectuur op biopten en opvolgende radicale prostatectomieën. Patiënten toonden 
cribriforme architectuur in 69% van de radicale prostatectomieën, echter slechts 30% van de 
biopten bevatten dit patroon. Patiënten met Grade Group 2 prostaatkanker hadden fout-negatieve 
biopten voor cribriforme groei in 40% van de gevallen. Deze patiënten presenteerden zich met 




Het aantal fout-negatieve biopten lag echter lager voor patiënten met groot cribriforme groei, het 
agressieve subtype van cribriforme architectuur. Daarnaast was biochemisch recidief-vrije 
overleving significant slechter voor patiënten met waar-positieve dan fout-negatieve biopten. 
Hoewel cribriforme architectuur geassocieerd is met een somberdere uitkomst, is de afwezigheid 
van dit patroon minder goed onderzocht. Hoofdstuk 4 vergeleek de kenmerken en uitkomsten van 
Grade Group 1 en Grade Group 2 prostaatkanker zonder cribriforme architectuur. Ondanks het 
feit dat patiënten met cribriform-negatieve Grade Group 2 prostaatkanker hogere PSA levels en 
tumorstadium toonden, alsmede dat zij vaker positieve snijvlakken hadden, beïnvloedde dit niet 
de lange termijn uitkomsten. Metastasen en ziekte-specifiek overlijden kwamen niet voor in Grade 
Group 1 noch in cribriform-negatieve Grade Group 2 prostaatkanker. Biochemisch recidief-vrije 
overleving was korter in cribriform-negatieve Grade Group 2 patiënten, echter deze overleving is 
mede gerelateerd aan tumorvolume en chirurgische techniek, welke niet noodzakelijk 
samenhangen met biologisch gedrag van de tumor. 
Glomeruloïde groei toont gelijkenissen met cribriforme architectuur en is tot dusverre weinig 
onderzocht. Glomerulaties met kleine intraluminale protusies zijn geassocieerd met betere 
prostaatkanker overleving. Het klinische gedrag van complexe glomeruloïde patronen, welke 
cribriform aspect kunnen tonen, is nog onduidelijk. Hoofdstuk 5 richtte zich op karakterisatie van 
glomerulaties in radicale prostatectomieën. Complexe glomeruloïde groei werd vaak samen gezien 
met andere cribriforme patronen en was geassocieerd met enigszins minder gunstigere 
clinicopathologische kenmerken. Desalniettemin werd er geen onafhankelijke prognostische 
waarde gevonden voor simpele noch complexe glomeruloïde groei. Daarom dient glomeruloïde 
groei niet gekenmerkt te worden als subtype van cribriforme groei. 
Hoofdstuk 6 onderzocht de groeipatronen in Grade Group 4 prostaatkanker. Het meewegen van 
groeipatronen in de prostaatkanker diagnose heeft misschien de meeste waarde voor klinische 
besluitvorming in Grade Group 2 patiënten, het kan eveneens aanvullende waarde tonen voor 
hooggradige prostaatkanker. Cribriforme architectuur werd onderzocht in Grade Group 4 
prostaatkanker waar het in 62% van de gevallen voorkwam. Het werd vaker gezien in Gleason 
score 4+4 dan 3+5 of 5+3 prostaatkanker en vaak samen met solide groeipatronen. De 
aanwezigheid van cribriforme architectuur was een onafhankelijke parameter voor biochemisch 
recidief- en metastase-vrije overleving. Daarom heeft cribriforme architectuur toegevoegde waarde 
in de risicostratificatie van Gleason score 8 prostaatkanker patiënten. 
Tenslotte worden in hoofdstuk 7 de bevindingen van dit proefschrift uiteengezet en beoordeeld in 
het licht van huidige kennis over prostaatkanker groeipatronen. We betogen dat incorporatie van 
cribriforme architectuur de gepersonaliseerde klinische besluitvorming van prostaatkanker 
patiënten kan verbeteren. 
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